[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 151
1. Winget M, Hossain S, Yasui Y, Scarfe A: Characteristics of patients with stage III colon adenocarcinoma who fail to receive guideline-recommended treatment. Cancer; 2010 Oct 15;116(20):4849-56
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characteristics of patients with stage III colon adenocarcinoma who fail to receive guideline-recommended treatment.
  • BACKGROUND: Many patients with stage III colon adenocarcinoma do not receive adjuvant chemotherapy despite the proven survival advantage it offers.
  • To enhance the provision of optimal cancer care, patient characteristics associated with not receiving guideline-adherent treatment must be identified among patients with operable, stage III colon adenocarcinoma.
  • METHODS: This was a population-based, retrospective study of all patients who underwent surgery for stage III colon adenocarcinoma diagnosed from 2002 through 2005 in Alberta, Canada.
  • RESULTS: Of the 772 patients who underwent surgery for stage III colon adenocarcinoma and met the eligibility criteria, 618 patients (80%) had a consultation with an oncologist.
  • CONCLUSIONS: The current results indicated that the proportion of patients with stage III colon adenocarcinoma who did not receive treatment according to evidence-based guidelines was appreciable.
  • [MeSH-major] Adenocarcinoma / drug therapy. Chemotherapy, Adjuvant. Colonic Neoplasms / drug therapy. Guideline Adherence

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 American Cancer Society.
  • (PMID = 20578180.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] Canada / Canadian Institutes of Health Research / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


2. Sträter J, Herter I, Merkel G, Hinz U, Weitz J, Möller P: Expression and prognostic significance of APAF-1, caspase-8 and caspase-9 in stage II/III colon carcinoma: caspase-8 and caspase-9 is associated with poor prognosis. Int J Cancer; 2010 Aug 15;127(4):873-80

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression and prognostic significance of APAF-1, caspase-8 and caspase-9 in stage II/III colon carcinoma: caspase-8 and caspase-9 is associated with poor prognosis.
  • To study their prognostic influence in colon carcinoma, expression of APAF-1, caspase-8 and caspase-9 was determined by immunohistochemistry in normal colon mucosa (n = 8) and R0-resected stage II/III colon carcinomas (n >or= 124) using a semiquantitative score.
  • In normal colon, APAF-1 and caspase-8 are most strongly expressed in the luminal surface epithelium, whereas caspase-9 is expressed all along the crypt axis.
  • In colon carcinomas, there is considerable variability in the expression of these proapoptotic factors, although complete loss of caspase-8 and caspase-9 is rare.
  • The influence of caspase-8 expression was mainly seen in patients with stage III colon carcinoma (p = 0.011), whereas the prognostic influence of caspase-9 expression was significant in stage II cases (p = 0.037) and just failed to be significant in stage III tumors (p = 0.0581).
  • Our data suggest that, in colon carcinomas, expression of caspase-8 and caspase-9 is significantly associated with poor survival.
  • Caspase-9 may be an independent prognosticator in colon carcinoma.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenocarcinoma, Mucinous / metabolism. Apoptotic Protease-Activating Factor 1 / metabolism. Biomarkers, Tumor / metabolism. Caspase 8 / metabolism. Caspase 9 / metabolism. Colonic Neoplasms / metabolism
  • [MeSH-minor] Aged. Colon / metabolism. Female. Humans. Immunoenzyme Techniques. Male. Middle Aged. Neoplasm Staging. Prognosis. Prospective Studies. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20013803.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / APAF1 protein, human; 0 / Apoptotic Protease-Activating Factor 1; 0 / Biomarkers, Tumor; EC 3.4.22.- / Caspase 8; EC 3.4.22.- / Caspase 9
  •  go-up   go-down


3. Puppa G, Maisonneuve P, Sonzogni A, Masullo M, Chiappa A, Valerio M, Zampino MG, Franceschetti I, Capelli P, Chilosi M, Menestrina F, Viale G, Pelosi G: Independent prognostic value of fascin immunoreactivity in stage III-IV colonic adenocarcinoma. Br J Cancer; 2007 Apr 10;96(7):1118-26
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Independent prognostic value of fascin immunoreactivity in stage III-IV colonic adenocarcinoma.
  • In this study, we investigated the expression of fascin in 228 advanced colonic adenocarcinoma patients with a long follow-up.
  • Fascin correlated significantly with sex, tumour grade and stage, mucinous differentiation, number of metastatic lymph nodes, extranodal tumour extension, and the occurrence of distant metastases.
  • [MeSH-major] Adenocarcinoma / metabolism. Carrier Proteins / metabolism. Colonic Neoplasms / metabolism. Microfilament Proteins / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1993 Feb 15;71(4):1368-83 [8435813.001]
  • [Cites] J Cutan Pathol. 2002 Aug;29(7):430-8 [12139639.001]
  • [Cites] Am J Pathol. 1996 Feb;148(2):593-600 [8579121.001]
  • [Cites] In Vivo. 1996 Mar-Apr;10(2):153-60 [8744794.001]
  • [Cites] J Cell Biol. 1996 Sep;134(5):1271-81 [8794867.001]
  • [Cites] Hum Pathol. 1996 Nov;27(11):1124-34 [8912819.001]
  • [Cites] Dis Colon Rectum. 1997 Jan;40(1):15-24 [9102255.001]
  • [Cites] Mol Biol Cell. 1997 Nov;8(11):2345-63 [9362073.001]
  • [Cites] Mol Biol Cell. 1998 May;9(5):993-1006 [9571235.001]
  • [Cites] J Cell Biol. 1998 Oct 5;143(1):121-33 [9763425.001]
  • [Cites] J Biol Chem. 1999 Feb 26;274(9):5443-53 [10026156.001]
  • [Cites] CA Cancer J Clin. 2004 Nov-Dec;54(6):295-308 [15537574.001]
  • [Cites] Ann Surg. 2002 Oct;236(4):416-21; discussion 421 [12368669.001]
  • [Cites] Am J Pathol. 2003 Jan;162(1):69-80 [12507891.001]
  • [Cites] J Clin Oncol. 2003 Jan 15;21(2):241-50 [12525515.001]
  • [Cites] Br J Cancer. 2003 Feb 24;88(4):537-47 [12592367.001]
  • [Cites] Eur J Cancer. 2003 Apr;39(6):718-27 [12651195.001]
  • [Cites] Lung Cancer. 2003 Nov;42(2):203-13 [14568688.001]
  • [Cites] J Clin Oncol. 2004 May 1;22(9):1572-82 [15117979.001]
  • [Cites] Histopathology. 1986 May;10(5):437-59 [3721406.001]
  • [Cites] J Cell Biol. 1986 Aug;103(2):631-40 [3525578.001]
  • [Cites] Cell Struct Funct. 1988 Oct;13(5):373-85 [3224379.001]
  • [Cites] Oncology. 2004;67(3-4):262-70 [15557788.001]
  • [Cites] Surg Oncol. 2004 Aug-Nov;13(2-3):93-101 [15572091.001]
  • [Cites] Clin Cancer Res. 2005 Jan 1;11(1):186-92 [15671545.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Clin Cancer Res. 2005 Apr 1;11(7):2597-605 [15814639.001]
  • [Cites] Int J Biochem Cell Biol. 2005 Sep;37(9):1787-804 [16002322.001]
  • [Cites] Hum Pathol. 2005 Jul;36(7):741-6 [16084942.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Nov 11;337(1):355-62 [16185662.001]
  • [Cites] Semin Oncol. 2005 Dec;32(6 Suppl 8):11-4 [16360006.001]
  • [Cites] Clin Colorectal Cancer. 2006 May;6(1):38-45 [16796790.001]
  • [Cites] Eur J Cardiothorac Surg. 2006 Sep;30(3):538-42 [16870459.001]
  • [Cites] J Clin Pathol. 2006 Sep;59(9):958-64 [16524962.001]
  • [Cites] BMC Cancer. 2006;6:241 [17029629.001]
  • [Cites] Hepatogastroenterology. 2003 Sep-Oct;50(53):1362-6 [14571738.001]
  • [Cites] J Histochem Cytochem. 2000 Feb;48(2):163-6 [10639482.001]
  • [Cites] Cancer. 2000 Apr 1;88(7):1739-57 [10738234.001]
  • [Cites] Br J Cancer. 2000 Oct;83(7):870-3 [10970687.001]
  • [Cites] Clin Exp Metastasis. 2000;18(1):83-8 [11206843.001]
  • [Cites] J Cell Biol. 2001 Mar 19;152(6):1169-82 [11257118.001]
  • [Cites] Nature. 2001 May 17;411(6835):375-9 [11357145.001]
  • [Cites] Cancer. 2001 Dec 1;92(11):2754-9 [11753948.001]
  • [Cites] Bioessays. 2002 Apr;24(4):350-61 [11948621.001]
  • [Cites] Am J Clin Pathol. 2002 Jul;118(1):52-9 [12109856.001]
  • [Cites] DNA Cell Biol. 1994 Aug;13(8):821-7 [8068206.001]
  • (PMID = 17375048.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Carrier Proteins; 0 / Microfilament Proteins; 146808-54-0 / fascin
  • [Other-IDs] NLM/ PMC2360113
  •  go-up   go-down


Advertisement
4. Weissenberger C, Geissler M, Otto F, Barke A, Henne K, von Plehn G, Rein A, Muller C, Bartelt S, Henke M: Anemia and long-term outcome in adjuvant and neoadjuvant radiochemotherapy of stage II and III rectal adenocarcinoma: the Freiburg experience (1989-2002). World J Gastroenterol; 2006 Mar 28;12(12):1849-58
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anemia and long-term outcome in adjuvant and neoadjuvant radiochemotherapy of stage II and III rectal adenocarcinoma: the Freiburg experience (1989-2002).
  • METHODS: Two hundred and eighty-six patients with Union International Contre Cancer (UICC) stage II and III rectal adenocarcinomas, who underwent resection by conventional surgical techniques (low anterior or abdominoperineal resection), received either postoperative (n=233) or preoperative (n=53) radiochemotherapy from January 1989 until July 2002.
  • RESULTS: Anemia before radiochemotherapy was an independent prognostic factor for improved DFS (risk ratio 0.76, P=0.04) as well as stage, grading, R status (free radial margins), type of surgery, carcinoembryonic antigen (CEA) levels, and gender.
  • Stage, grading, R status (free radial margins), type of surgery, CEA levels, and gender have predictive value for the outcome of rectal cancer.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / radiotherapy. Anemia / etiology. Rectal Neoplasms / drug therapy. Rectal Neoplasms / radiotherapy

  • Genetic Alliance. consumer health - Anemia.
  • MedlinePlus Health Information. consumer health - Anemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1991 Mar 14;324(11):709-15 [1997835.001]
  • [Cites] Strahlenther Onkol. 2004 Jan;180(1):45-51 [14704844.001]
  • [Cites] Dis Colon Rectum. 1992 Nov;35(11):1057-65 [1425050.001]
  • [Cites] World J Surg. 1992 Sep-Oct;16(5):858-65 [1462620.001]
  • [Cites] Lancet. 1993 Feb 20;341(8843):457-60 [8094488.001]
  • [Cites] Dis Colon Rectum. 1993 Jun;36(6):564-72 [8500374.001]
  • [Cites] Dis Colon Rectum. 1994 Jan;37(1):73-87 [8287751.001]
  • [Cites] Am J Clin Oncol. 1995 Aug;18(4):277-81 [7625365.001]
  • [Cites] Int J Colorectal Dis. 1995;10(3):126-32 [7561427.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Jan 15;37(2):305-11 [9069301.001]
  • [Cites] Br J Surg. 1997 Mar;84(3):352-7 [9117306.001]
  • [Cites] Anticancer Res. 1997 Mar-Apr;17(2B):1379-82 [9137502.001]
  • [Cites] Dis Colon Rectum. 1997 Jul;40(7):866-7 [9221868.001]
  • [Cites] Anticancer Res. 1997 Jul-Aug;17(4B):2935-8 [9329568.001]
  • [Cites] Strahlenther Onkol. 1998 Dec;174 Suppl 4:31-4 [9879345.001]
  • [Cites] Langenbecks Arch Surg. 1998 Dec;383(6):416-26 [9921941.001]
  • [Cites] Ann Surg. 1999 Oct;230(4):544-52; discussion 552-4 [10522724.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2412-8 [10561304.001]
  • [Cites] Cancer. 1999 Nov 15;86(10):1952-8 [10570418.001]
  • [Cites] Int J Biol Markers. 2000 Jan-Mar;15(1):51-5 [10763141.001]
  • [Cites] Int J Colorectal Dis. 2000 Feb;15(1):9-20 [10766086.001]
  • [Cites] Curr Opin Oncol. 2001 Jul;13(4):300-6 [11429489.001]
  • [Cites] J Clin Oncol. 2001 Sep 15;19(18):3895-902 [11559727.001]
  • [Cites] N Engl J Med. 2004 Oct 21;351(17):1731-40 [15496622.001]
  • [Cites] Br J Surg. 1984 Jan;71(1):12-6 [6689962.001]
  • [Cites] JAMA. 1990 Sep 19;264(11):1444-50 [2202842.001]
  • [Cites] N Engl J Med. 2001 Oct 11;345(15):1091-7 [11596588.001]
  • [Cites] Rev Invest Clin. 2001 Sep-Oct;53(5):388-95 [11795103.001]
  • [Cites] J Clin Oncol. 2002 Apr 1;20(7):1744-50 [11919230.001]
  • [Cites] J Clin Oncol. 2002 Apr 1;20(7):1751-8 [11919231.001]
  • [Cites] Eur J Cancer. 2002 May;38(7):919-36 [11978517.001]
  • [Cites] Am Surg. 2002 May;68(5):482-7 [12013294.001]
  • [Cites] Am J Surg. 2002 May;183(5):504-8 [12034381.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Oct 1;54(2):386-96 [12243812.001]
  • [Cites] Eur J Cancer Care (Engl). 2002 Sep;11(3):166-72 [12296832.001]
  • [Cites] J Exp Clin Cancer Res. 2002 Sep;21(3):329-35 [12385573.001]
  • [Cites] Surg Clin North Am. 2002 Oct;82(5):1035-58 [12507208.001]
  • [Cites] J Clin Oncol. 1992 Apr;10(4):549-57 [1548520.001]
  • (PMID = 16609990.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ PMC4087509
  •  go-up   go-down


5. Phelip JM, Molinié F, Delafosse P, Launoy G, Trétarre B, Bara S, Buémi A, Velten M, Danzon A, Ganry O, Bouvier AM, Grosclaude P, Faivre J: A population-based study of adjuvant chemotherapy for stage-II and -III colon cancers. Gastroenterol Clin Biol; 2010 Feb;34(2):144-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A population-based study of adjuvant chemotherapy for stage-II and -III colon cancers.
  • BACKGROUND: Although clinical trials have demonstrated that adjuvant chemotherapy improves survival for stage-III colon cancer, the benefits remain controversial for stage-II lesions.
  • The objective of the present study was to determine the extent to which adjuvant chemotherapy is used for patients with stage-II and -III colon cancers.
  • METHODS: The study population comprised 1074 patients with stage-II and -III colon cancers diagnosed in 2000 in 12 French administrative districts and recorded in population-based cancer registries.
  • RESULTS: Overall, 20.4% of patients with stage II and 61.9% with stage III received adjuvant chemotherapy.
  • Among stage-II patients, those receiving chemotherapy decreased from 57.6% in patients aged <or=50 years to 1.1% in those aged >or=85.
  • The corresponding percentages with stage III were 93.6% and 1.4%.
  • In multivariate analyses, other factors found to be independently and significantly associated with administration of adjuvant chemotherapy for stage II were extension of the cancer (stage IIA vs. stage IIB), clinical presentation (obstruction or perforation vs. uncomplicated cancer) and discussion of the case at a multidisciplinary case-review meeting.
  • For stage III, apart from age, discussion of the case at a multidisciplinary meeting was the only factor independently associated with administration of chemotherapy.
  • CONCLUSION: Adjuvant chemotherapy for stage-III colon cancer is used extensively for patients under 75 years of age.
  • On the other hand, a substantial percentage of stage-II colon cancer patients receive adjuvant chemotherapy despite its uncertain benefits.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Colonic Neoplasms / drug therapy. Colonic Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 Elsevier Masson SAS. All rights reserved.
  • (PMID = 20079591.001).
  • [ISSN] 0399-8320
  • [Journal-full-title] Gastroentérologie clinique et biologique
  • [ISO-abbreviation] Gastroenterol. Clin. Biol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] France
  •  go-up   go-down


6. Wirtzfeld DA, Mikula L, Gryfe R, Ravani P, Dicks EL, Parfrey P, Gallinger S, Pollett WG: Concordance with clinical practice guidelines for adjuvant chemotherapy in patients with stage I-III colon cancer: experience in 2 Canadian provinces. Can J Surg; 2009 Apr;52(2):92-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concordance with clinical practice guidelines for adjuvant chemotherapy in patients with stage I-III colon cancer: experience in 2 Canadian provinces.
  • The American Society of Clinical Oncology and Cancer Care Ontario have recommended adjuvant chemotherapy for patients with high-risk stage II colon cancer.
  • We evaluated differences in concordance with guidelines in the treatment of patients with stage I-III colon cancer in the Canadian provinces of Newfoundland and Labrador and Ontario.
  • METHODS: We assessed clinical data and treatment from January 1999 to December 2000 for 130 patients from Newfoundland and Labrador and 315 patients from Ontario who had stage I-III colon cancer.
  • We evaluated factors affecting the use of chemotherapy in patients with stage II disease.
  • RESULTS: No patients received adjuvant therapy for stage I disease.
  • Forty-five of 52 patients (87%) in Newfoundland and Labrador and 108 of 115 patients (94%) in Ontario received adjuvant chemotherapy for stage III colon cancer.
  • Twenty of 55 patients (36%) in Newfoundland and Labrador and 44 of 116 patients (38%) in Ontario received adjuvant therapy for stage II disease.
  • There was a strong trend toward using chemotherapy in patients with stage II disease who were 50 years or younger, independent of high-risk status.
  • CONCLUSION: Concordance with CPGs for adjuvant chemotherapy in patients with stage II colon cancer was not optimal.
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Adult. Age Factors. Aged. Humans. Middle Aged. Multivariate Analysis. Newfoundland and Labrador. Ontario. Patient Selection. Registries. Risk Assessment

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] JAMA. 1999 Oct 20;282(15):1458-65 [10535437.001]
  • [Cites] Am J Gastroenterol. 2006 Jun;101(6):1320-8 [16771956.001]
  • [Cites] Arch Pathol Lab Med. 2000 Jul;124(7):979-94 [10888773.001]
  • [Cites] Chronic Dis Can. 2000;21(2):81-6 [11007659.001]
  • [Cites] N Engl J Med. 2003 Jul 17;349(3):247-57 [12867608.001]
  • [Cites] N Engl J Med. 2004 Jun 3;350(23):2335-42 [15175435.001]
  • [Cites] N Engl J Med. 2004 Jul 22;351(4):337-45 [15269313.001]
  • [Cites] J Clin Oncol. 2004 Aug 15;22(16):3395-407 [15199087.001]
  • [Cites] J Clin Oncol. 2004 Aug 15;22(16):3408-19 [15199089.001]
  • [Cites] Intern Med J. 2004 Aug;34(8):492-500 [15317548.001]
  • [Cites] JAMA. 1990 Sep 19;264(11):1444-50 [2202842.001]
  • [Cites] CMAJ. 1993 Feb 15;148(4):507-12 [8431814.001]
  • [Cites] N Engl J Med. 1993 May 13;328(19):1365-71 [8474513.001]
  • [Cites] N Engl J Med. 1993 Dec 30;329(27):1977-81 [8247072.001]
  • [Cites] J Clin Oncol. 1995 Feb;13(2):502-12 [7844612.001]
  • [Cites] Eur J Cancer. 1995 Jul-Aug;31A(7-8):1369-72 [7577053.001]
  • [Cites] Nat Med. 1995 Apr;1(4):348-52 [7585065.001]
  • [Cites] J Clin Oncol. 1999 May;17(5):1349-55 [10334518.001]
  • [Cites] J Clin Oncol. 1999 May;17(5):1356-63 [10334519.001]
  • [Cites] Med Care Res Rev. 2004 Dec;61(4):453-73 [15536209.001]
  • [Cites] Health Aff (Millwood). 2005 Jan-Feb;24(1):18-28 [15647212.001]
  • [Cites] Cancer. 2005 Apr 25;105(2):101-9 [15643601.001]
  • [Cites] Eval Health Prof. 2006 Mar;29(1):65-88 [16510880.001]
  • [Cites] Qual Health Care. 1999 Sep;8(3):177-83 [10847875.001]
  • (PMID = 19399202.001).
  • [ISSN] 1488-2310
  • [Journal-full-title] Canadian journal of surgery. Journal canadien de chirurgie
  • [ISO-abbreviation] Can J Surg
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Canada
  • [Other-IDs] NLM/ PMC2663496
  •  go-up   go-down


7. Morris M, Platell C, Fritschi L, Iacopetta B: Failure to complete adjuvant chemotherapy is associated with adverse survival in stage III colon cancer patients. Br J Cancer; 2007 Mar 12;96(5):701-7
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Failure to complete adjuvant chemotherapy is associated with adverse survival in stage III colon cancer patients.
  • Two recent North American studies have shown that completion of 5-fluorouracil (5FU)-based adjuvant chemotherapy is a major prognostic factor for the survival of elderly stage III colon cancer patients.
  • The study cohort comprised 851 stage III colon cancer patients treated by surgery alone and 461 who initiated the Mayo chemotherapy regime.
  • The current and previous studies demonstrate the importance of completing adjuvant 5-FU-based chemotherapy for colon cancer.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / mortality. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Colonic Neoplasms / drug therapy. Colonic Neoplasms / mortality

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2002 Sep 1;20(17):3605-16 [12202661.001]
  • [Cites] J Clin Oncol. 2002 Mar 15;20(6):1491-8 [11896096.001]
  • [Cites] J Clin Oncol. 2002 Oct 1;20(19):3992-8 [12351596.001]
  • [Cites] Br J Cancer. 2003 May 19;88(10):1510-5 [12771914.001]
  • [Cites] Br J Cancer. 2003 Jun 16;88(12):1859-65 [12799627.001]
  • [Cites] J Clin Oncol. 2003 Aug 1;21(15):2896-903 [12885807.001]
  • [Cites] Clin Cancer Res. 2003 Aug 1;9(8):2898-903 [12912934.001]
  • [Cites] J Clin Oncol. 2003 Oct 15;21(20):3729-36 [14551292.001]
  • [Cites] Clin Cancer Res. 2003 Dec 1;9(16 Pt 1):5860-5 [14676107.001]
  • [Cites] N Engl J Med. 2004 Jun 3;350(23):2343-51 [15175436.001]
  • [Cites] Oncology (Williston Park). 2004 May;18(6):751-5; discussion 755-8 [15214594.001]
  • [Cites] Eur J Cancer. 2004 Oct;40(15):2230-6 [15454247.001]
  • [Cites] J Clin Oncol. 1988 Oct;6(10):1653-64 [3049954.001]
  • [Cites] N Engl J Med. 1990 Feb 8;322(6):352-8 [2300087.001]
  • [Cites] JAMA. 1990 Sep 19;264(11):1444-50 [2202842.001]
  • [Cites] J Clin Oncol. 1992 Jul;10(7):1171-5 [1607921.001]
  • [Cites] J Clin Oncol. 1993 Oct;11(10):1879-87 [8410113.001]
  • [Cites] J Clin Oncol. 1994 Jun;12(6):1291-5 [8201391.001]
  • [Cites] J Clin Oncol. 1997 Jan;15(1):246-50 [8996149.001]
  • [Cites] J Clin Oncol. 1998 Nov;16(11):3537-41 [9817272.001]
  • [Cites] Eur J Cancer. 1998 Nov;34(12):1871-5 [10023308.001]
  • [Cites] Cancer. 2005 Mar 15;103(6):1165-71 [15693031.001]
  • [Cites] J Clin Oncol. 2005 Mar 20;23(9):1819-25 [15774775.001]
  • [Cites] N Engl J Med. 2005 Jun 30;352(26):2696-704 [15987918.001]
  • [Cites] N Engl J Med. 2005 Jun 30;352(26):2746-8 [15987925.001]
  • [Cites] JAMA. 2005 Dec 7;294(21):2703-11 [16333005.001]
  • [Cites] Dig Surg. 2005;22(6):401-14 [16479107.001]
  • [Cites] J Natl Cancer Inst. 2006 May 3;98(9):610-9 [16670386.001]
  • [Cites] J Clin Oncol. 2006 May 20;24(15):2368-75 [16618946.001]
  • [Cites] J Clin Oncol. 2007 Jan 1;25(1):102-9 [17194911.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2412-8 [10561304.001]
  • [Cites] Br J Cancer. 2001 Mar 2;84(5):600-3 [11237378.001]
  • [Cites] Ann Intern Med. 2002 Mar 5;136(5):349-57 [11874307.001]
  • [Cites] J Clin Oncol. 2002 Sep 1;20(17):3617-27 [12202662.001]
  • (PMID = 17299387.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ PMC2360063
  •  go-up   go-down


8. Law CC, Fu YT, Chau KK, Choy TS, So PF, Wong KH: Toxicity profile and efficacy of oral capecitabine as adjuvant chemotherapy for Chinese patients with Stage III colon cancer. Dis Colon Rectum; 2007 Dec;50(12):2180-7
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Toxicity profile and efficacy of oral capecitabine as adjuvant chemotherapy for Chinese patients with Stage III colon cancer.
  • PURPOSE: The Xeloda in Adjuvant Cancer Therapy trial, conducted in a white population of patients, established capecitabine (Xeloda) as adjuvant chemotherapy for Stage III colon cancer.
  • Given the ethnical difference in toxicity of adjuvant chemotherapy in colon cancer, this study was designed to evaluate the safety and efficacy of adjuvant capecitabine in Chinese patients with colon cancer.
  • METHODS: Chinese patients with curatively resected Stage III colon adenocarcinoma, who received adjuvant capecitabine, were entered into a prospective database.
  • CONCLUSIONS: A different toxicity profile of adjuvant capecitabine was noted in this study on Chinese patients with colon cancer compared with that reported in the Xeloda in Adjuvant Cancer Therapy trial, whereas the efficacy outcomes were comparable.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antimetabolites, Antineoplastic / administration & dosage. Antimetabolites, Antineoplastic / adverse effects. Colonic Neoplasms / drug therapy. Deoxycytidine / analogs & derivatives. Fluorouracil / analogs & derivatives

  • Genetic Alliance. consumer health - Oral cancer.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17963003.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Prodrugs; 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; U3P01618RT / Fluorouracil
  •  go-up   go-down


9. Chin CC, Wang JY, Yeh CY, Kuo YH, Huang WS, Yeh CH: Metastatic lymph node ratio is a more precise predictor of prognosis than number of lymph node metastases in stage III colon cancer. Int J Colorectal Dis; 2009 Nov;24(11):1297-302
Genetic Alliance. consumer health - Metastatic cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic lymph node ratio is a more precise predictor of prognosis than number of lymph node metastases in stage III colon cancer.
  • OBJECTIVE: The objective of this study is to assess the value of metastatic lymph node ratio (LNR) in predicting disease-free survival (DFS) in patients with stage III adenocarcinoma of the colon.
  • MATERIALS AND METHODS: From 1995 to 2003 inclusively, a total of 624 patients featuring stage III adenocarcinoma of the colon underwent curative resection.
  • In T3/4LNR1 patients (n = 411), there was no difference in survival between those with N1 stage and those with N2 stage.
  • Cox proportional hazards regression analysis revealed that N stage (number of positive lymph nodes) was not a significant factor when LNR was taken into consideration.
  • CONCLUSIONS: LNR is a more precise predictor of 5-year DFS than number of positive lymph nodes (N stage) in patients with stage III colon cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19479270.001).
  • [ISSN] 1432-1262
  • [Journal-full-title] International journal of colorectal disease
  • [ISO-abbreviation] Int J Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


10. Georgescu SO, Neacşu CN, Vintilă D, Popa P, Forţu L, Nistor A, Ferariu D, Târcoveanu E: [Long-term results after surgery for colorectal adenocarcinoma, stage I-III. Problems of prognosis]. Rev Med Chir Soc Med Nat Iasi; 2007 Oct-Dec;111(4):932-9
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Long-term results after surgery for colorectal adenocarcinoma, stage I-III. Problems of prognosis].
  • [Transliterated title] Rezultate la distanţă după tratamentul chirurgical al adenocarcinomului colo-rectal stadiile I-III. Probleme de prognostic.
  • STUDY DESIGN: Prospective study on 142 consecutively cases with stage I to III colorectal adenocarcinomas (TNM AJCC/UICC) in which patients underwent potentially curative surgery in one single public health service (1st Surgical Clinic Iaşi, Romania) between 2004 and 2005.
  • The surgical procedures performed were the following: right colectomy (n = 54; 30%); transverse colectomy (n = 2; 1.4%); left colectomy (n = 19; 13.4%); segmental colon resection with anastomosis (n = 5 ; 3.5%); Hartmann procedure (n = 18; 12.7%); anterior rectal resection (n = 11; 7.7%) and abdominoperineal resection (n = 33; 23.2%).
  • RESULTS: The factors with a significant negative influence in overall survival and 42-months survival rates were: the age over 70 years, the emergency surgery related to cancer's complications, the advanced AJCC/ UICC stage, vascular invasion, perineural invasion, the recurrence of disease, the moderate and lower differentiated adenocarcinoma and incomplete or not performed chemotherapy.
  • CONCLUSION: Even with a radical surgical approach the advanced stage of colorectal adenocarcinoma has a low prognostic, but some other factors have also a high significance in postoperative outcome.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / surgery. Colectomy / methods. Colorectal Neoplasms / pathology. Colorectal Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18389783.001).
  • [ISSN] 0048-7848
  • [Journal-full-title] Revista medico-chirurgicală̆ a Societă̆ţ̜ii de Medici ş̧i Naturaliş̧ti din Iaş̧i
  • [ISO-abbreviation] Rev Med Chir Soc Med Nat Iasi
  • [Language] rum
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Romania
  •  go-up   go-down


11. Vaccaro CA, Im V, Rossi GL, Quintana GO, Benati ML, Perez de Arenaza D, Bonadeo FA: Lymph node ratio as prognosis factor for colon cancer treated by colorectal surgeons. Dis Colon Rectum; 2009 Jul;52(7):1244-50
Genetic Alliance. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymph node ratio as prognosis factor for colon cancer treated by colorectal surgeons.
  • PURPOSE: This study was designed to assess the prognostic value of the lymph node ratio in patients with colon cancer treated by colorectal specialists.
  • METHODS: Three hundred and sixty-two Stage III consecutive cases were analyzed based on quartiles: lymph node ratio 1 (>0 and <0.06); lymph node ratio 2 (between 0.06 and 0.12); lymph node ratio 3 (>0.12 and <0.25); lymph node ratio 4 (>or=0.25).
  • CONCLUSION: A lymph node ratio >or=0.25 was an independent prognostic factor in Stage III colon adenocarcinoma regardless of the number positive nodes.
  • [MeSH-major] Adenocarcinoma / mortality. Adenocarcinoma / pathology. Colonic Neoplasms / mortality. Colonic Neoplasms / pathology. Lymph Node Excision. Lymph Nodes / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19571700.001).
  • [ISSN] 1530-0358
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Mori T, Hirota T, Ohashi Y, Kodaira S, Prospective Trial of Adjuvant Chemotherapy for Colon Cancer Study Group (PAC): Significance of histologic type of primary lesion and metastatic lymph nodes as a prognostic factor in stage III colon cancer. Dis Colon Rectum; 2006 Jul;49(7):982-92
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Significance of histologic type of primary lesion and metastatic lymph nodes as a prognostic factor in stage III colon cancer.
  • PURPOSE: This study was designed to investigate whether the histologic types of the primary lesion and of metastatic lymph nodes in Stage III colon cancer are useful as prognostic factors.
  • METHODS: Stage III colon cancer patients were enrolled and were divided into two groups: Group W, in which the histologic type of both primary tumors and metastatic lymph nodes was well-differentiated adenocarcinoma; and Group U, in which the primary tumors and the metastatic lymph nodes were of any type other than well-differentiated.
  • CONCLUSIONS: In Stage III colon cancer, the prognosis of cases whose primary lesion and lymph node tissues are both well differentiated is extremely good.
  • [MeSH-major] Adenocarcinoma / pathology. Colonic Neoplasms / pathology

  • Genetic Alliance. consumer health - Metastatic cancer.
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16625329.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Alkylating Agents; 0 / Antimetabolites, Antineoplastic; 50SG953SK6 / Mitomycin; U3P01618RT / Fluorouracil
  •  go-up   go-down


13. Muc-Wierzgon M, Nowakowska-Zajdel E, Kokot T, Kozowicz A, Wiczkowski A, Grochowska-Niedworok E, Mazurek U, Wierzgon J: Genetic disregulation of TNF alpha and TNF alpha type II receptors in colon cancer at the II and III stage of disease. J Biol Regul Homeost Agents; 2006 Jan-Jun;20(1-2):10-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic disregulation of TNF alpha and TNF alpha type II receptors in colon cancer at the II and III stage of disease.
  • The expression of the genes coding TNFalpha and TNF RII receptors (TNF RII: TNFR2 membrane and soluble domain, TNFR2/R7 soluble domain) was analysed in colon cancer at the II and III stage of disease, by estimation of mRNA expression.
  • The study included 80 patients with histopathologically confirmed adenocarcinoma.
  • The highest number of mRNA TNF-alpha copies were investigated in all samples of tissue and independently of the stage of disease.
  • Simultaneously, we noticed the largest number of mRNA copies for TNFalpha and TNF R2/R7 in healthy cells at stage III of the disease.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18088549.001).
  • [ISSN] 0393-974X
  • [Journal-full-title] Journal of biological regulators and homeostatic agents
  • [ISO-abbreviation] J. Biol. Regul. Homeost. Agents
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / Receptors, Tumor Necrosis Factor, Type II; 0 / Tumor Necrosis Factor-alpha
  •  go-up   go-down


14. Perazzo F, Denninghoff V, Pasccon G, Pallotta MG, Tatangelo M, Cuartero V, Kirchuck R, Chacón M, Gennari L, Vera K, Avagnina A: Preliminary report of the mutation status of KRAS and BRAF-V600E in an Argentinean population of primary colorectal tumors. J Clin Oncol; 2009 May 20;27(15_suppl):e22183

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The primary tumor site was 21.9% (32) right colon, 5.5% (8) transverse colon, 45.2% (66) left colon and 27.4%(40) rectal cancer.
  • Adenocarcinoma was the unique histotype and mucinous differentiation was observed in 14.7% (21).
  • The Pathological Stage at diagnosis was Stage I 3.42% (5), II 24% (35), III 33.6% (49) and IV 39% (57).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963599.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Bayraktar UD, Bayraktar S, Herna S, Ku N, Jones C, Merchan J, Sands LR, Marchetti F, Montero A, Rocha-Lima CM: Does delay of adjuvant chemotherapy affect the clinical outcome in patients with colon cancer? J Clin Oncol; 2009 May 20;27(15_suppl):4046

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Does delay of adjuvant chemotherapy affect the clinical outcome in patients with colon cancer?
  • : 4046 Background: Adjuvant chemotherapy (AC) in patients with stage III colon adenocarcinoma prevents recurrences and improves survival.
  • We hypothesized that AC commenced within 60 days of resection would increase survival in patients with stage II and III colon cancer.
  • METHODS: Patients with newly diagnosed stage II or III colon adenocarcinoma who received fluoropyrimidine based AC in two centers (a private cancer center and a large community hospital) between 2000 and 2007 were included into analysis.
  • 116 patients (61%) were female and 35 patients (18%) had stage II disease.
  • The only difference between the two groups was the higher N stage in group 1.
  • The treating hospital and the N stage were found to be the factors affecting the OS in univariate analysis.
  • CONCLUSIONS: Delay of AC more than 60 days after resection is associated with inferior survival in stage II/III colon cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961564.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Kim J, Chae Y, Sohn S, Kang B, Lee S, Lim K, Choi G, Baek J: -93G&gt;A polymorphism of hMLH1 associated with prognosis for patients with colorectal cancer. J Clin Oncol; 2009 May 20;27(15_suppl):4039

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Three hundred and ninety- seven consecutive patients with curatively resected colorectal adenocarcinoma were enrolled in the present study.
  • RESULTS: The median age of the patients was 63 years (range, 21-85), and 218 (54.9%) patients had colon cancer and 179 (45.1%) patients rectal cancer.
  • Pathologic stages after surgery were as follows: stage 0/I (n=86, 21.7%), stage II (n=146, 36.8%), stage III (n=145, 36.5%), and stage IV (n=20, 5.0%).
  • Multivariate survival analysis including stage, differentiation, age, and CEA level showed that the survival for the patients with the -93AA genotype of hMLH1 was worse than for the patients with the combined -93GG and GA genotype (overall survival: hazard ratio [HR]=2.953, 95% Confidential Interval [CI], 1.273-6.850, P=0.012; disease-free survival: HR=2.299, 95% CI, 1.417-3.730, P=0.001), whereas the other polymorphisms were not associated with survival.
  • Accordingly, in addition to the pathologic stage, the analysis of -93G>A polymorphism of hMLH1 can help identify patient subgroups at high risk of a poor disease outcome.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961540.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Overman MJ, Hu C, Wolff RA, Chang GJ: Impact of lymph node evaluation on survival for small bowel adenocaricnoma: Analysis of the Surveillance, Epidemiology and End Results (SEER) database. J Clin Oncol; 2009 May 20;27(15_suppl):4596

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 4596 Background: Small bowel adenocarcinoma is a rare malignancy and is often associated with poor outcome.
  • METHODS: Patients aged 18-90 with adenocarcinoma of the small intestine diagnosed between 1988 and 2005 were identified from SEER data (ver. 2008).
  • Cox proportional hazards regression analyses were performed after adjusting for age, sex, race, T stage, grade, and primary site.
  • Stage I-II cases were categorized by total LN examined (1-8, 9-12, and >12).
  • Stage III cases were evaluated using cut-point analysis to determine the number of positive LN that predicted outcomes.
  • Survival among stage I/II patients (n=1,216) was dependent upon the total number of LN assessed.
  • 5-year DSS for stage II patients was 66%, 82% (HR 0.52 95% CI .33-.84), and 88% (HR 0.38, 95% CI .23-.61) for 1-8, 9-12, >12 LN, respectively.
  • The optimal cutpoint of positive LN for stage III disease (n=775) was <3 compard to ≥3 with 5 year DSS of 58% vs. 37% (HR 1.49, 95% CI 1.15-1.92, P=0.002), respectively.
  • Among stage III patients, the LNR was even more predictive of survival than stratification by the number of positive lymph nodes as demonstrated by an improved chi-square statistic for the multivariate model (78.8 vs 63.1, P=0.0005).
  • CONCLUSIONS: As noted in colon cancer, the total number of LN assessed has considerable influence upon survival in stage I, II and III small bowel adenocarcinoma.
  • Stratifying stage III small bowel adenocarcinoma into those with <3 and ≥3 positive lymph nodes significantly improves prognostication for these patients and future staging systems should incorporate the number of positive nodes into nodal staging.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963112.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Carson HJ, Krivit JS, Eilers SG: Metastasis of colonic adenocarcinoma to the external ear canal: an unusual case with a complex-pattern of disease progression. Ear Nose Throat J; 2005 Jan;84(1):36-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastasis of colonic adenocarcinoma to the external ear canal: an unusual case with a complex-pattern of disease progression.
  • We report on a patient who developed far-ranging metastases of adenocarcinoma of the colon that followed a gradual cephalad progression, including the right external ear canal, and led to hearing loss.
  • The patient was a 63-year-old white male with stage III adenocarcinoma of the colon.
  • Physical examination of the head and neck showed a mass in the external ear canal, and biopsy confirmed adenocarcinoma.
  • The significance of such wide-ranging metastases is that metastasis of adenocarcinoma to the ear did not signal imminent death, and relief of the hearing loss it caused was possible.
  • [MeSH-major] Adenocarcinoma / secondary. Colonic Neoplasms / pathology. Ear Canal. Ear Neoplasms / secondary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15742771.001).
  • [ISSN] 0145-5613
  • [Journal-full-title] Ear, nose, & throat journal
  • [ISO-abbreviation] Ear Nose Throat J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Asaad SM, Jubelirer SJ, Welch CA: Prognostic indicators for stage II (Dukes' stage B) adenocarcinoma of the colon. W V Med J; 2005 Sep-Oct;101(5):210-3

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic indicators for stage II (Dukes' stage B) adenocarcinoma of the colon.
  • To determine the prognostic indicators that are associated with lower disease free survival (DFS) and overall survival (OS) in stage II colon cancer patients, the tumor registry records were reviewed for all patients diagnosed with stage II and III adenocarcinoma of the colon at Charleston Area Medical Center from 1986 to 1994.
  • The prognostic indicators of 174 stage II patients who had not undergone treatment were assessed for DFS and OS.
  • In addition, DFS and OS curves for stage II patients with < 7 LNR were not significantly different from survival curves for stage III patients.
  • Treatment decisions are made based primarily on stage, and stage II patients are not routinely offered adjuvant therapy.
  • [MeSH-major] Adenocarcinoma / mortality. Adenocarcinoma / pathology. Colonic Neoplasms / mortality. Colonic Neoplasms / pathology. Neoplasm Staging. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16422269.001).
  • [ISSN] 0043-3284
  • [Journal-full-title] The West Virginia medical journal
  • [ISO-abbreviation] W V Med J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Jensen SA, Vilmar A, Sørensen JB: Adjuvant chemotherapy in elderly patients (&gt;or=75 yr) completely resected for colon cancer stage III compared to younger patients: toxicity and prognosis. Med Oncol; 2006;23(4):521-31
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant chemotherapy in elderly patients (>or=75 yr) completely resected for colon cancer stage III compared to younger patients: toxicity and prognosis.
  • PURPOSE: To compare benefits and risks to adjuvant chemotherapy following complete resection of node-positive colon cancer stage III for patients aged >or=75 yr and younger.
  • CONCLUSIONS: Adjuvant 5-FU chemotherapy should be considered for elderly patients aged >or=75 yr in good performance at high risk of recurrence of colon carcinoma after resection.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Colonic Neoplasms / drug therapy

  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17303911.001).
  • [ISSN] 1357-0560
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


21. Zaanan A, Cuilliere-Dartigues P, Guilloux A, Parc Y, Louvet C, de Gramont A, Tiret E, Dumont S, Gayet B, Validire P, Fléjou JF, Duval A, Praz F: Impact of p53 expression and microsatellite instability on stage III colon cancer disease-free survival in patients treated by 5-fluorouracil and leucovorin with or without oxaliplatin. Ann Oncol; 2010 Apr;21(4):772-80
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of p53 expression and microsatellite instability on stage III colon cancer disease-free survival in patients treated by 5-fluorouracil and leucovorin with or without oxaliplatin.
  • BACKGROUND: The aim was to determine the values of p53 tumour expression and microsatellite instability (MSI) phenotype to predict benefit from adjuvant chemotherapy of colon cancer by 5-fluorouracil and leucovorin (FL) alone or with oxaliplatin (FOLFOX).
  • PATIENTS AND METHODS: This retrospective study included 233 unselected patients with stage III colon cancer treated by FL (n = 124) or FOLFOX (n = 109).
  • CONCLUSION: Our observations indicate that MSI status and p53 expression may influence the impact of oxaliplatin on adjuvant treatment of stage III colon cancer patients.

  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19833818.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 0 / Tumor Suppressor Protein p53; 04ZR38536J / oxaliplatin; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


22. Haller DG, Catalano PJ, Macdonald JS, O'Rourke MA, Frontiera MS, Jackson DV, Mayer RJ: Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: final report of Intergroup 0089. J Clin Oncol; 2005 Dec 1;23(34):8671-8
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: final report of Intergroup 0089.
  • PURPOSE: In 1990, fluorouracil (FU) plus levamisole for 1 year became standard adjuvant treatment for patients with high-risk stages II and III colon cancer.
  • INT-0089 has long-term follow-up of the largest clinical trial of patients with high-risk colon cancer, documenting not only the durability of the treatment effects, but also the natural history of patients with high-risk colon cancer, and analyses of treatment based on age, race, and comorbid conditions such as obesity, diabetes, and second primary cancers.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Colonic Neoplasms / drug therapy

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16314627.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA15488; United States / NCI NIH HHS / CA / CA21115; United States / NCI NIH HHS / CA / CA23318; United States / NCI NIH HHS / CA / CA32291; United States / NCI NIH HHS / CA / CA66636
  • [Publication-type] Clinical Trial, Phase III; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 12001-76-2 / Vitamin B Complex; 2880D3468G / Levamisole; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


23. Dahl O, Fluge Ø, Carlsen E, Wiig JN, Myrvold HE, Vonen B, Podhorny N, Bjerkeset O, Eide TJ, Halvorsen TB, Tveit KM, Norwegian Gastrointestinal Cancer Group: Final results of a randomised phase III study on adjuvant chemotherapy with 5 FU and levamisol in colon and rectum cancer stage II and III by the Norwegian Gastrointestinal Cancer Group. Acta Oncol; 2009;48(3):368-76
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Final results of a randomised phase III study on adjuvant chemotherapy with 5 FU and levamisol in colon and rectum cancer stage II and III by the Norwegian Gastrointestinal Cancer Group.
  • BACKGROUND: The recommendation of adjuvant chemotherapy for colon cancer with lymph node metastases, based on two studies from USA, was reluctantly accepted by Norwegian medical doctors.
  • MATERIAL AND METHODS: Four hundred and twenty five patients with operable colon and rectum cancer, Stage II and III (Dukes' stage B and C), were from January 1993 to October 1996, included in a randomised multicentre trial in Norway.
  • There was no difference between the two groups when analysed for colon and rectum separately.
  • However, the subgroup of colon cancer with stage III exhibited a statistically significant difference both for DFS, 58% vs. 37% (p=0.012) and CSS, 65% vs. 47% (p=0.032) in favour of adjuvant chemotherapy.
  • CONCLUSIONS: Colon cancer patients with lymph node metastases benefit from adjuvant chemotherapy with 5-FU/Lev with acceptable toxicity.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents / therapeutic use. Antirheumatic Agents / therapeutic use. Colonic Neoplasms / drug therapy. Fluorouracil / therapeutic use. Levamisole / therapeutic use. Rectal Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19242829.001).
  • [ISSN] 1651-226X
  • [Journal-full-title] Acta oncologica (Stockholm, Sweden)
  • [ISO-abbreviation] Acta Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] Norway
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antirheumatic Agents; 2880D3468G / Levamisole; U3P01618RT / Fluorouracil
  •  go-up   go-down


24. Jacob BP, Salky B: Laparoscopic colectomy for colon adenocarcinoma: an 11-year retrospective review with 5-year survival rates. Surg Endosc; 2005 May;19(5):643-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopic colectomy for colon adenocarcinoma: an 11-year retrospective review with 5-year survival rates.
  • BACKGROUND: Laparoscopic colectomy for the management of colon cancer remains a controversial therapeutic option, especially when the outcomes are compared with the historically accepted survival data and recurrence rates after open surgery.
  • The purpose of this study was to evaluate the 5-year overall and disease-free survival rates after laparoscopic colon resection for invasive colon adenocarcinoma.
  • METHODS: A total of 129 patients underwent consecutive laparoscopic colectomies for colon adenocarcinoma (between April 1992 and 2004 January) by a single surgeon at a single institution.
  • RESULTS: After patients with noninvasive disease on final pathology were excluded, the study population comprised 88 patients who underwent laparoscopic colectomies for invasive colon cancer with > 2 years of follow-up.
  • The Kaplan-Meier survival data were as follows for 5-year overall survival and 5-year disease-free survival, respectively stage I (n = 34) 89% and 89%; stage II (n = 22), 65% and 59%; stage III (n = 19), 72% and 67%; stages I-III combined, (n = 75), 77% and 73%.
  • CONCLUSIONS: For this specific cohort of patients undergoing curative laparoscopic colectomies for invasive colon adenocarcinoma, the mean follow-up was > 5 years.
  • Overall survival and disease-free survival for stage I, II, and III colon cancer as well as for stages I-III combined are favorable and comparable to historically acceptable open colectomy survival rates.
  • Overall survival and disease-free survival after laparoscopic colectomy for invasive colon cancer is no worse, and perhaps better than, the previously reported rates for the same procedure done by an open technique.
  • [MeSH-major] Adenocarcinoma / surgery. Colectomy / methods. Colonic Neoplasms / surgery. Laparoscopy / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Surg Endosc. 2006 Jun;20(6):996-7 [16739001.001]
  • (PMID = 15789256.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


25. Schippinger W, Samonigg H, Schaberl-Moser R, Greil R, Thödtmann R, Tschmelitsch J, Jagoditsch M, Steger GG, Jakesz R, Herbst F, Hofbauer F, Rabl H, Wohlmuth P, Gnant M, Thaler J, Austrian Breast and Colorectal Cancer Study Group: A prospective randomised phase III trial of adjuvant chemotherapy with 5-fluorouracil and leucovorin in patients with stage II colon cancer. Br J Cancer; 2007 Oct 22;97(8):1021-7
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A prospective randomised phase III trial of adjuvant chemotherapy with 5-fluorouracil and leucovorin in patients with stage II colon cancer.
  • The purpose of this trial was to investigate the efficacy of adjuvant chemotherapy with 5-fluorouracil (5-FU) and leucovorin (LV) in stage II colon cancer.
  • Patients with stage II colon cancer were randomised to either adjuvant chemotherapy with 5-FU/LV (100 mg m(-2) LV+450 mg m(-2) 5-FU weekly, weeks 1-6, in 8 weeks cycles x 7) or surveillance only.
  • In conclusion, results of this trial demonstrate a trend to a lower risk for relapse in patients treated with adjuvant 5-FU/LV for stage II colon cancer.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Colonic Neoplasms / drug therapy. Neoplasm Recurrence, Local / prevention & control

  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1999 Nov;17(11):3553-9 [10550154.001]
  • [Cites] Ann Surg. 2006 Oct;244(4):602-10 [16998369.001]
  • [Cites] CA Cancer J Clin. 2003 Jan-Feb;53(1):5-26 [12568441.001]
  • [Cites] J Clin Oncol. 2003 Aug 1;21(15):2912-9 [12885809.001]
  • [Cites] N Engl J Med. 2004 Jun 3;350(23):2343-51 [15175436.001]
  • [Cites] J Clin Oncol. 2004 Aug 15;22(16):3395-407 [15199087.001]
  • [Cites] J Clin Oncol. 2004 Aug 15;22(16):3408-19 [15199089.001]
  • [Cites] Cancer Chemother Rep. 1966 Mar;50(3):163-70 [5910392.001]
  • [Cites] Biometrics. 1975 Mar;31(1):103-15 [1100130.001]
  • [Cites] J Natl Cancer Inst. 1988 Mar 2;80(1):30-6 [3276901.001]
  • [Cites] Arch Surg. 1989 Feb;124(2):180-2 [2916939.001]
  • [Cites] N Engl J Med. 1990 Feb 8;322(6):352-8 [2300087.001]
  • [Cites] J Clin Oncol. 1990 Sep;8(9):1466-75 [2202789.001]
  • [Cites] J Clin Oncol. 1993 Oct;11(10):1879-87 [8410113.001]
  • [Cites] Ann Intern Med. 1995 Mar 1;122(5):321-6 [7847642.001]
  • [Cites] J Clin Oncol. 1999 May;17(5):1349-55 [10334518.001]
  • [Cites] J Clin Oncol. 1999 May;17(5):1356-63 [10334519.001]
  • [Cites] Eur J Cancer. 2001 Oct;37 Suppl 8:S4-66 [11602373.001]
  • (PMID = 17895886.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] England
  • [Chemical-registry-number] Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ PMC2360441
  •  go-up   go-down


26. Roth AD, Tejpar S, Delorenzi M, Yan P, Fiocca R, Klingbiel D, Dietrich D, Biesmans B, Bodoky G, Barone C, Aranda E, Nordlinger B, Cisar L, Labianca R, Cunningham D, Van Cutsem E, Bosman F: Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol; 2010 Jan 20;28(3):466-74
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial.
  • We took advantage of PETACC-3, an adjuvant trial with 3,278 patients with stage II to III colon cancer, to evaluate the prognostic value of KRAS and BRAF tumor mutation status in this setting.
  • RESULTS: KRAS and BRAF tumor mutation rates were 37.0% and 7.9%, respectively, and were not significantly different according to tumor stage.
  • In a multivariate analysis containing stage, tumor site, nodal status, sex, age, grade, and microsatellite instability (MSI) status, KRAS mutation was associated with grade (P = .0016), while BRAF mutation was significantly associated with female sex (P = .017), and highly significantly associated with right-sided tumors, older age, high grade, and MSI-high tumors (all P < 10(-4)).
  • CONCLUSION: In stage II-III colon cancer, the KRAS mutation status does not have major prognostic value.
  • [MeSH-major] Adenocarcinoma / genetics. Colonic Neoplasms / genetics. Proto-Oncogene Proteins / genetics. Proto-Oncogene Proteins B-raf / genetics. ras Proteins / genetics

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20008640.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / KRAS protein, human; 0 / Proto-Oncogene Proteins; EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf; EC 3.6.5.2 / ras Proteins
  •  go-up   go-down


27. Read TE, Fleshman JW, Caushaj PF: Sentinel lymph node mapping for adenocarcinoma of the colon does not improve staging accuracy. Dis Colon Rectum; 2005 Jan;48(1):80-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sentinel lymph node mapping for adenocarcinoma of the colon does not improve staging accuracy.
  • PURPOSE: This study was designed to: determine the efficacy of sentinel lymph node mapping in patients with intraperitoneal colon cancer; and create an algorithm to predict potential survival benefit by using best-case estimates in favor of sentinel node mapping and lymph node ultraprocessing techniques.
  • METHODS: Forty-one patients with intraperitoneal colon cancer undergoing colectomy with curative intent were studied prospectively.
  • After mobilization of the colon and mesentery, 1 to 2 ml of isosulfan blue dye was injected subserosally around the tumor.
  • Stage of disease in the remaining 38 patients was: I, n = 10 (26 percent); II, n = 15 (39 percent); III, n = 11 (29 percent); IV, n = 2 (5 percent).
  • To create a survival benefit algorithm, we assumed the following: combined fraction of Stage I and II disease (0.5); fraction understaged by bivalving and hematoxylin and eosin staining that would have occult positive nodes by more sophisticated analysis (0.15); fraction of occult positive nodes detected by sentinel node mapping (0.9); and survival benefit from chemotherapy (0.33).
  • CONCLUSIONS: Sentinel node mapping with isosulfan blue dye and routine processing of retrieved nodes does not improve staging accuracy in patients with intraperitoneal colon cancer.
  • [MeSH-major] Adenocarcinoma / pathology. Algorithms. Colonic Neoplasms / pathology. Neoplasm Staging / methods. Sentinel Lymph Node Biopsy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15690662.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


28. Kuebler JP, Colangelo L, O'Connell MJ, Smith RE, Yothers G, Begovic M, Robinson B, Seay TE, Wolmark N: Severe enteropathy among patients with stage II/III colon cancer treated on a randomized trial of bolus 5-fluorouracil/leucovorin plus or minus oxaliplatin: a prospective analysis. Cancer; 2007 Nov 1;110(9):1945-50
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Severe enteropathy among patients with stage II/III colon cancer treated on a randomized trial of bolus 5-fluorouracil/leucovorin plus or minus oxaliplatin: a prospective analysis.
  • BACKGROUND: Cases of severe gastrointestinal toxicity were monitored prospectively during NSABP C-07, a randomized clinical trial of adjuvant therapy for patients with stage II/III colon cancer.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Colonic Diseases / chemically induced. Colonic Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Colonic Diseases.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17853393.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00004931
  • [Grant] United States / NCI NIH HHS / CA / U10-CA-12027; United States / NCI NIH HHS / CA / U10-CA-37377; United States / NCI NIH HHS / CA / U10-CA-69651; United States / NCI NIH HHS / CA / U10-CA-69974
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


29. Paduch R, Kandefer-Szerszeń M: Transforming growth factor-beta1 (TGF-beta1) and acetylcholine (ACh) alter nitric oxide (NO) and interleukin-1beta (IL-1beta) secretion in human colon adenocarcinoma cells. In Vitro Cell Dev Biol Anim; 2009 Oct;45(9):543-50
Hazardous Substances Data Bank. NITRIC OXIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transforming growth factor-beta1 (TGF-beta1) and acetylcholine (ACh) alter nitric oxide (NO) and interleukin-1beta (IL-1beta) secretion in human colon adenocarcinoma cells.
  • Colon adenocarcinoma is one of the most common fatal malignancies in Western countries.
  • The present study was conducted to assess the influence of recombinant human transforming growth factor (rhTGF)-beta1 or ACh on nitric oxide (NO) and interleukin-1beta (IL-1beta) secretion by three human colon adenocarcinoma cell lines: HT29, LS180, and SW948, derived from different grade tumors (Duke's stage).
  • Colon carcinoma cells exhibited different sensitivities to rhTGF-beta1 or ACh dependent on the tumor grade and the culture model.
  • ACh exhibited significant inhibitory effects towards NO, endothelial nitric oxide synthase (eNOS), and IL-1beta secretion especially by tumor cells derived form Duke's C stage of colon carcinoma. rhTGF-beta1 also decreased NO, IL-1beta, and eNOS expression, but its effect was lower than that observed after the administration of ACh.
  • Taken together, the TGF-beta1-ACh axis may regulate colon carcinoma progression and metastasis by altering NO secretion and influence inflammatory responses by modulating IL-1beta production.
  • [MeSH-minor] Cell Line, Tumor. Enzyme-Linked Immunosorbent Assay. Humans. Nitric Oxide Synthase Type III / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19551451.001).
  • [ISSN] 1543-706X
  • [Journal-full-title] In vitro cellular & developmental biology. Animal
  • [ISO-abbreviation] In Vitro Cell. Dev. Biol. Anim.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Interleukin-1beta; 0 / Transforming Growth Factor beta1; 31C4KY9ESH / Nitric Oxide; EC 1.14.13.39 / Nitric Oxide Synthase Type III; N9YNS0M02X / Acetylcholine
  •  go-up   go-down


30. Chin CC, Wang JY, Changchien CR, Huang WS, Tang R: Carcinoma obstruction of the proximal colon cancer and long-term prognosis--obstruction is a predictor of worse outcome in TNM stage II tumor. Int J Colorectal Dis; 2010 Jul;25(7):817-22
MedlinePlus Health Information. consumer health - Intestinal Obstruction.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carcinoma obstruction of the proximal colon cancer and long-term prognosis--obstruction is a predictor of worse outcome in TNM stage II tumor.
  • PURPOSE: Colon obstruction is suggested to be a predictor of poor outcome in colon cancer.
  • However, the effect of obstruction on outcome in patients with different tumor-nodes-metastases (TNM) stage cancer has not been fully addressed.
  • The aim of this study is to determine whether colon obstruction predicts surgical and long-term oncologic outcomes in patients with proximal colon cancer.
  • METHODS: A total of 1,492 consecutive patients underwent open resection of primary adenocarcinoma of right colon in a single institution between January 1995 and December 2005.
  • Univariate and multivariate analyses were performed to identify colon obstruction and other predictors of surgical and oncologic outcomes.
  • RESULTS: Among 1,492 patients, 306 (20.5%) patients presented with colon obstruction.
  • Obstruction predicted a worse long-term disease-free survival (DFS) among patients with stage II-III disease (log-rank test, p = 0.0003).
  • The data were stratified by TNM stage.
  • Obstruction predicted a worse DFS among patients with TNM stage II cancer (598 patients; log-rank test, p = 0.001; Cox regression, p = 0.012), but it was not a predictor in TNM stage III cancer patients (424 patients; p = 0.116; p = 0.108).
  • CONCLUSIONS: Colon obstruction was an independent predictor of long-term outcome only in TNM stage II but not in stage III proximal colon cancer.
  • Patients with TNM stage II obstructive colon cancer could be included in future trials of adjuvant therapies.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20135321.001).
  • [ISSN] 1432-1262
  • [Journal-full-title] International journal of colorectal disease
  • [ISO-abbreviation] Int J Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


31. Song W, He YL, Cai SR, Zhang CH, Chen CQ, Peng JJ, Zhan WH: [Clinical features of colorectal mucinous adenocarcinoma]. Zhonghua Wei Chang Wai Ke Za Zhi; 2009 Sep;12(5):487-90
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical features of colorectal mucinous adenocarcinoma].
  • OBJECTIVE: To investigate the clinicopathological characteristics and prognosis of colorectal mucinous adenocarcinoma (MAC) and non-mucinous adenocarcinoma (NMAC).
  • METHODS: Clinical data of 2089 cases with colorectal cancer from 1994 to 2007 in our hospital, including 169 patients diagnosed as mucinous adenocarcinoma were analyzed retrospectively.
  • The rates of tumor location in colon (97 cases,57.4% vs 814 cases, 44.3%, in MAC and NMAC) were significantly different (P<0.01).
  • The rate of radical resection (86.4% vs 91.5%), hepatic metastasis (5.3% vs 8.5%) and local recurrence had no significant difference between patients with mucinous and non-mucinous adenocarcinoma (P>0.05).
  • In comparison to NMAC patients, MAC patients were worse in long-term overall survival, the survival of receiving radical resection and of TNM stage (II+III) group (P<0.01).
  • Survivals were not significantly different in TNM stage I and IV groups between mucinous and non-mucinous adenocarcinoma (P>0.05).
  • CONCLUSIONS: Colorectal mucinous adenocarcinoma patients have worse outcome in comparison to non-mucinous adenocarcinoma patients.
  • Mucinous adenocarcinoma may have special biological behavior, which is an independent prognostic factor for patients with colorectal cancer.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Colorectal Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19742341.001).
  • [ISSN] 1671-0274
  • [Journal-full-title] Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  • [ISO-abbreviation] Zhonghua Wei Chang Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


32. Wick MR, Vitsky JL, Ritter JH, Swanson PE, Mills SE: Sporadic medullary carcinoma of the colon: a clinicopathologic comparison with nonhereditary poorly differentiated enteric-type adenocarcinoma and neuroendocrine colorectal carcinoma. Am J Clin Pathol; 2005 Jan;123(1):56-65
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sporadic medullary carcinoma of the colon: a clinicopathologic comparison with nonhereditary poorly differentiated enteric-type adenocarcinoma and neuroendocrine colorectal carcinoma.
  • We studied 68 sporadic colorectal carcinomas (CRCs) with medullary features (MCRCs) and compared them with 35 poorly differentiated purely "enteric" CRCs (ECRCs) and 15 purely neuroendocrine carcinomas (NECs) of grades II and III, all in patients lacking a family history of CRC.
  • MCRCs were significantly more common in the ascending colon than were ECRCs, but there was no significant dissimilarity to NECs.
  • Despite an infiltrative growth pattern, MCRC was less likely than ECRC to manifest with stage III or IV disease, but there was no stage-related difference from NECs.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma, Medullary / pathology. Carcinoma, Neuroendocrine / pathology. Colorectal Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15762280.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


33. Sprenger T, Rothe H, Jung K, Christiansen H, Conradi LC, Ghadimi BM, Becker H, Liersch T: Stage II/III rectal cancer with intermediate response to preoperative radiochemotherapy: do we have indications for individual risk stratification? World J Surg Oncol; 2010;8:27
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stage II/III rectal cancer with intermediate response to preoperative radiochemotherapy: do we have indications for individual risk stratification?
  • METHODS: From a prospective database of 496 patients with rectal adenocarcinoma, 107 patients with stage II/III cancers and intermediate response to preoperative 5-FU based RCT (ypT2/3 and TRG 2/3), treated within the German Rectal Cancer Trials were studied.
  • Furthermore, ypT stage and tumor grading turn out to be additional auxiliary factors.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Rectal Neoplasms / pathology. Rectal Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Clinical Trials, Phase II as Topic. Clinical Trials, Phase III as Topic. Combined Modality Therapy. Female. Fluorouracil / administration & dosage. Humans. Lymph Nodes / pathology. Lymph Nodes / surgery. Male. Middle Aged. Neoadjuvant Therapy. Neoplasm Staging. Organoplatinum Compounds / administration & dosage. Preoperative Care. Prospective Studies. Risk Assessment. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Rectal Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2007 Jan 1;25(1):110-7 [17194912.001]
  • [Cites] J Clin Oncol. 2007 Jun 20;25(18):2573-9 [17577036.001]
  • [Cites] J Clin Oncol. 2007 Oct 1;25(28):4379-86 [17906203.001]
  • [Cites] Clin Cancer Res. 2007 Nov 15;13(22 Pt 1):6617-23 [18006762.001]
  • [Cites] Dis Colon Rectum. 2008 Mar;51(3):277-83 [18183463.001]
  • [Cites] Cancer. 2008 Jul 1;113(1):57-64 [18442099.001]
  • [Cites] J Surg Oncol. 2009 Dec 1;100(7):525-8 [19697351.001]
  • [Cites] Cancer. 2009 Dec 1;115(23):5432-40 [19673001.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2010 Jul 15;77(4):1158-65 [19800178.001]
  • [Cites] J Clin Oncol. 2001 Jan 1;19(1):157-63 [11134208.001]
  • [Cites] N Engl J Med. 2001 Aug 30;345(9):638-46 [11547717.001]
  • [Cites] Cancer. 2001 Dec 1;92(11):2754-9 [11753948.001]
  • [Cites] Arch Surg. 2002 Feb;137(2):206-10 [11822961.001]
  • [Cites] J Clin Oncol. 2002 Apr 1;20(7):1729-34 [11919228.001]
  • [Cites] ANZ J Surg. 2002 Jul;72(7):483-7 [12123507.001]
  • [Cites] Dis Colon Rectum. 2002 Jul;45(7):895-903 [12130878.001]
  • [Cites] Semin Surg Oncol. 2003;21(1):19-22 [12923912.001]
  • [Cites] N Engl J Med. 2004 Oct 21;351(17):1731-40 [15496622.001]
  • [Cites] Br J Surg. 1982 Oct;69(10):613-6 [6751457.001]
  • [Cites] N Engl J Med. 1991 Mar 14;324(11):709-15 [1997835.001]
  • [Cites] Lancet. 1993 Feb 20;341(8843):457-60 [8094488.001]
  • [Cites] Z Gastroenterol. 2008 Aug;46(8):799-840 [18759205.001]
  • [Cites] Ann Surg. 2009 Jun;249(6):965-72 [19474683.001]
  • [Cites] J Surg Oncol. 2009 Oct 1;100(5):387-91 [19582821.001]
  • [Cites] N Engl J Med. 1997 Apr 3;336(14):980-7 [9091798.001]
  • [Cites] Int J Colorectal Dis. 1997;12(1):19-23 [9112145.001]
  • [Cites] N Engl J Med. 1997 Jul 31;337(5):346-7; author reply 347-8 [9235500.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Dec 1;42(5):935-41 [9869213.001]
  • [Cites] Dis Colon Rectum. 1999 Feb;42(2):167-73 [10211491.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Feb 1;61(2):426-31 [15667963.001]
  • [Cites] Cancer. 2005 Feb 1;103(3):647-9 [15612025.001]
  • [Cites] Surg Today. 2005;35(6):442-5 [15912290.001]
  • [Cites] J Clin Oncol. 2005 Dec 1;23(34):8688-96 [16246976.001]
  • [Cites] Ann Surg. 2006 Apr;243(4):492-8 [16552200.001]
  • [Cites] Dis Colon Rectum. 2006 Sep;49(9):1284-92 [16758130.001]
  • [Cites] J Clin Oncol. 2006 Oct 1;24(28):4620-5 [17008704.001]
  • (PMID = 20388220.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ PMC2864265
  •  go-up   go-down


34. Giuliani A, Demoro M, Corona M, Di Bari M, Ricciardulli T, Galati G, Ciardi A: Synchronous colon and gastric advanced carcinomas. J Exp Clin Cancer Res; 2005 Mar;24(1):155-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synchronous colon and gastric advanced carcinomas.
  • An unusual case of advanced synchronous colon and gastric carcinoma is described.
  • A 36 year old female was admitted to our Department with a stenosing right colon cancer diagnosed at endoscopy which was performed for lower crampy abdominal pain and gross blood in the stool.
  • Multiple colon polyps, distal to the tumor, were also detected.
  • On preoperative abdominal computed tomography, a stenosing right colon cancer, without evidence of abdominal diffusion, was confirmed.
  • At laparotomy, in addition to colon cancer, an antral gastric cancer was incidentally found.
  • At histology, a poorly differentiated gastric adenocarcinoma with signet ring-cell component (pT2, pN0; stage IB) and a moderately differentiated colon adenocarcinoma with a tubulovillous component (pT3, pN1; stage III, Stage Dukes C) were revealed.

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15943046.001).
  • [ISSN] 0392-9078
  • [Journal-full-title] Journal of experimental & clinical cancer research : CR
  • [ISO-abbreviation] J. Exp. Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


35. Arfa N, Hamdani I, Gharbi L, Ben Abid S, Ghariani B, Mannai S, Mestiri H, Khalfallah MT, Mzabi SR: [Survival and prognostic factors of colorectal adenocarcinoma: analytic multifactor review of 150 cases]. Ann Chir; 2006 Feb;131(2):104-11
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Survival and prognostic factors of colorectal adenocarcinoma: analytic multifactor review of 150 cases].
  • [Transliterated title] Survie et facteurs pronostiques des adénocarcinomes colorectaux: étude analytique uni- et multifactorielle de 150 cas.
  • This study attempts to observe the survival of colorectal adenocarcinoma and to find prognostic factors and other variables potentially associated with outcome of colorectal adenocarcinoma.
  • MATERIAL AND METHODS: It's a retrospective study based on 150 patients with colorectal adenocarcinoma from 1990 to 2002.
  • 84 patients had colon adenocarcinoma and 66 patients had rectal adenocarcinoma.
  • In histological exam the adenocarcinoma was well differenced in 69 cases (46%), and undifferentiated in 17 cases (18, 3%).
  • There were 6 patients (4%) Dukes stage I TNM, 61 stage II (40, 7%), 51 stage III TNM (34%) and 32 patients stage IV TNM (34%).
  • All patients had surgical curative resection associated with adjuvant chemotherapy in 60 cases of colon adenocarcinoma and preoperative radiotherapy in 33 cases of rectal adenocarcinoma.
  • In addition to the clinical factors, we found of significant prognostic value undifferentiated adenocarcinoma and an elevated value of serum carcinoembryonic antigen>5 ng/ml.
  • [MeSH-major] Adenocarcinoma / mortality. Colorectal Neoplasms / mortality

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16443189.001).
  • [ISSN] 0003-3944
  • [Journal-full-title] Annales de chirurgie
  • [ISO-abbreviation] Ann Chir
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


36. Chen HH, Chakravarty K D, Wang JY, Changchien CR, Tang R: Pathological examination of 12 regional lymph nodes and long-term survival in stages I-III colon cancer patients: an analysis of 2,056 consecutive patients in two branches of same institution. Int J Colorectal Dis; 2010 Nov;25(11):1333-41

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pathological examination of 12 regional lymph nodes and long-term survival in stages I-III colon cancer patients: an analysis of 2,056 consecutive patients in two branches of same institution.
  • PURPOSE: Pathologic examination of at least 12 lymph nodes (LNs) is widely accepted as a standard for colon cancer surgery.
  • METHODS: Patients with stages I-III adenocarcinoma of the colon between 1998 and 2003 were identified from the Chang Gung Colorectal Tumor Registry in two branches (Linkou and Kaohsiung branches) of same institution.
  • Younger age, right hemicolectomy, larger tumor, higher tumor stage, higher caseload of surgeons, and patients at Linkou branch with an odds ratio (OR) as high as 23 (95% CI, 17-31) were independently associated with a higher frequency of ≥12 examined nodes.
  • Patients with examined node number of <12 had a greater risk of recurrence within stages II and III (stage II: adjusted OR 1.88, 95% CI 1.27-2.79; stage III: adjusted OR 1.58, 95% CI 1.15-2.17) but not within stage I (OR 0.73, 95% CI 0.23-2.24).
  • CONCLUSIONS: The results confirm that factors influencing nodal harvest are multifactorial and the examined LN number of 12 or more is associated with an increased long-term survival in stages II-III colon cancer.
  • It is possible to adequately sample and examine a sufficient number of nodes in the majority of colon cancer specimens by standardized conventional methods.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20676662.001).
  • [ISSN] 1432-1262
  • [Journal-full-title] International journal of colorectal disease
  • [ISO-abbreviation] Int J Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


37. Dahl O: [Adjuvant chemotherapy for colon cancer]. Tidsskr Nor Laegeforen; 2007 Nov 29;127(23):3094-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Adjuvant chemotherapy for colon cancer].
  • BACKGROUND: Radical resection is the main treatment for adenocarcinoma of the colon.
  • The background for adjuvant chemotherapy of colon cancer is presented.
  • RESULTS AND INTERPRETATION: Cure rates after curative resections of colon cancer (stage III) are improved by about 12% if patients are treated with adjuvant chemotherapy with oxaliplatin combined with 5-fluoruracil and folinat (or capecitabine) for 6 months.
  • Certain subgroups of stage II (Dukes' stage B) are also likely to benefit from adjuvant chemotherapy.
  • [MeSH-major] Adenocarcinoma / drug therapy. Colonic Neoplasms / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18049502.001).
  • [ISSN] 0807-7096
  • [Journal-full-title] Tidsskrift for den Norske lægeforening : tidsskrift for praktisk medicin, ny række
  • [ISO-abbreviation] Tidsskr. Nor. Laegeforen.
  • [Language] nor
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Norway
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Antineoplastic Agents
  • [Number-of-references] 35
  •  go-up   go-down


38. Yokoi K, Tanaka N, Furukawa K, Seya T, Ohaki Y, Tajiri T: Case of adenosquamous carcinoma of the ascending colon. J Nippon Med Sch; 2008 Aug;75(4):242-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Case of adenosquamous carcinoma of the ascending colon.
  • Adenocarcinoma accounts for most of the malignant tumors originating from the colon, whereas adenosquamous carcinoma is rare, accounting for about 0.1% of all colon cancers.
  • We present herein a case of adenosquamous carcinoma of the ascending colon.
  • A barium enema examination and lower gastrointestinal endoscopy showed a type 3 tumor in the ascending colon, and a biopsy confirmed the diagnosis of adenosquamous carcinoma.
  • Right hemicolectomy was performed, and the tumor was diagnosed as a stage III advanced colon cancer.
  • A search of Japanese literature over the past 25 years yielded 70 patients with adenosquamous carcinoma of the colon, and the clinicopathological features are discussed herein.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18781050.001).
  • [ISSN] 1345-4676
  • [Journal-full-title] Journal of Nippon Medical School = Nippon Ika Daigaku zasshi
  • [ISO-abbreviation] J Nippon Med Sch
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


39. Shaikh AJ, Raza S, Shaikh AA, Idress R, Kumar S, Rasheed YA, Lal A, Masood N: Demographics, pathologic patterns and long-term survival in operable colon cancers: local experience in Pakistan. Asian Pac J Cancer Prev; 2009 Jul-Sep;10(3):361-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Demographics, pathologic patterns and long-term survival in operable colon cancers: local experience in Pakistan.
  • BACKGROUND: Colon cancer is a common malignancy with its incidence reportedly rising in Asian countries, including Pakistan.
  • There are no comprehensive data available from Pakistan which focus on associations of various factors with long-term survival of colon cancer.
  • METHODOLOGY: In this retrospective study adult patients with colon cancer diagnosed through 2000-2003 were included.
  • Of the total, 49.5% of the patients had right sided (mortality rate 51.6%), 10.8% had transverse colon, (mortality rate 37.5%), 7.5% had descending colon (mortality rate 66.7%) and 32.2% had sigmoid colon (mortality rate 40.9%) cancers.
  • Stage I disease on diagnosis was found in 16%, stage II in 42.7 (mortality 40 %) and stage III in 41.3% (mortality 70 %).
  • Most patients had pure adenocarcinoma while a mucinous type differentiation was seen in 19.7%, 3% had signet ring morphology, 1.5% adeno-squamous carcinoma and similar number with neuroendocrine differentiation.
  • CONCLUSION: Colon cancer in Pakistan commonly presents at an advanced stage, there is a male preponderance, and relatively mean younger age at presentation for males is seen.
  • Advanced stage and lymph node involvement along with poorly differentiated pathology, signet ring or mucinous morphology, location in descending colon, positive surgical margins and removal of less than twelve lymph nodes are factors associated with poor long term survival.
  • There is a need to reinforce information about colon cancer and larger studies from the region are needed to confirm the factors analyzed here.
  • [MeSH-major] Adenocarcinoma / mortality. Adenocarcinoma / pathology. Colonic Neoplasms / mortality. Colonic Neoplasms / pathology. Neoplasm Recurrence, Local / mortality. Survivors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19640173.001).
  • [ISSN] 2476-762X
  • [Journal-full-title] Asian Pacific journal of cancer prevention : APJCP
  • [ISO-abbreviation] Asian Pac. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Thailand
  •  go-up   go-down


40. Snaebjörnsson P, Jónasson L, Jónsson T, Möller PH, Theodórs A, Jónasson JG: [Colon cancer in Iceland 1955-2004. Study on epidemiology, histopathology and gender difference]. Laeknabladid; 2009 Jun;95(6):423-30

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Colon cancer in Iceland 1955-2004. Study on epidemiology, histopathology and gender difference].
  • OBJECTIVE: Colon cancer is the third most common cancer in Iceland.
  • The aim of this study was to analyze the epidemiology and histopathology of colon cancer in Iceland, resection rate and the difference between men and women.
  • MATERIAL AND METHODS: Pathology and autopsy reports for all patients diagnosed with colon cancer between 1955 and 2004 where reviewed.
  • Most tumors were located in the sigmoid colon (35%).
  • Adenocarcinomas where 84% and mucinous adenocarcinoma 7%.
  • Altogether 7% of cases were TNM-stage I, 32% were stage II, 24% stage III, 21% in stage IV and stage was unknown in 16% of cases.
  • CONCLUSION: Incidence of colon cancer increased considerably, mainly for men.
  • Surgical rate and pathology of colon cancer is similar to that reported elsewhere except that there are somewhat fewer cases in TNM-stage I.
  • [MeSH-major] Adenocarcinoma / epidemiology. Adenocarcinoma, Mucinous / epidemiology. Colonic Neoplasms / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Laeknabladid. 2009 Jun;95(6):419 [19491405.001]
  • (PMID = 19491407.001).
  • [ISSN] 0023-7213
  • [Journal-full-title] Læknablađiđ
  • [ISO-abbreviation] Laeknabladid
  • [Language] ice
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Iceland
  •  go-up   go-down


41. Lee HY, Choi HJ, Park KJ, Shin JS, Kwon HC, Roh MS, Kim C: Prognostic significance of metastatic lymph node ratio in node-positive colon carcinoma. Ann Surg Oncol; 2007 May;14(5):1712-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of metastatic lymph node ratio in node-positive colon carcinoma.
  • BACKGROUND: The aim of this study was to evaluate the prognostic significance of the lymph node ratio between metastatic and examined lymph nodes (LNR) in patients with stage III colon cancer.
  • METHODS: A review was made of 201 patients (106 men) with stage III colon cancer of R0 resection.
  • CONCLUSIONS: Ratio-based LN staging, which reflects the number of LNs examined and the quality of LN dissection, is a potent modality for prognostic stratification in patients with LN-positive colon cancer.
  • [MeSH-major] Adenocarcinoma / secondary. Colonic Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Surg Oncol. 2007 Aug;14(8):2175-6 [17525836.001]
  • (PMID = 17253102.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


42. López-Cano M, Mañas MJ, Hermosilla E, Espín E: Multivisceral resection for colon cancer: analysis of prognostic factors. Dig Surg; 2010 Aug;27(3):238-45

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multivisceral resection for colon cancer: analysis of prognostic factors.
  • BACKGROUND/AIMS: To assess outcome of multivisceral resection in colon cancer patients and to identify predictors of survival.
  • METHODS: One hundred and thirteen consecutive patients with primary locally advanced colon cancer infiltrating adjacent organs undergoing multivisceral resection between 1998 and 2007 were reviewed.
  • The diagnosis was conventional adenocarcinoma in 94 patients.
  • Hematochezia and adjuvant chemotherapy were independent factors of favorable outcome and grade G3 and tumor stage III-IV of poor survival.
  • CONCLUSION: Hematochezia and adjuvant chemotherapy were associated with a better survival, and poorly differentiated tumors and stage IV disease with a poor survival.
  • [MeSH-minor] Abdomen, Acute. Adenocarcinoma / mortality. Adenocarcinoma / pathology. Adenocarcinoma / surgery. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Disease-Free Survival. Female. Follow-Up Studies. Gastrointestinal Hemorrhage / complications. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Recurrence

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20571272.001).
  • [ISSN] 1421-9883
  • [Journal-full-title] Digestive surgery
  • [ISO-abbreviation] Dig Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


43. Ianoşi G, Mercuţ D, Neagoe D, Ianoşi S, Drighiciu C, Resceanu A, Andriţoiu A, Manolache A: Histopathological factors as predictors for survival in colon and rectal cancers. Rom J Morphol Embryol; 2008;49(3):365-9
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histopathological factors as predictors for survival in colon and rectal cancers.
  • We included in our study 273 patients with colon and rectal cancers admitted in Surgical Clinic of Military Hospital of Craiova in which we evaluate the clinical-pathological features, location of the distant metastasis, postoperative staging, curability and survival.
  • We established correlations, inside of a same stage of the disease, for pathological features (characters of the tumors, differentiation grade and location) and survival rate.
  • Tumor differentiation is correlated with survival only for the patients with stage II and III of the disease, perineural invasion and pathologic N stage representing important predicting factors for a shorter survival.
  • Peritoneal washing for cytology prior to surgery is correlated with the stage of the disease and not with tumor differentiation.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / pathology. Colorectal Neoplasms / diagnosis. Colorectal Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18758642.001).
  • [ISSN] 1220-0522
  • [Journal-full-title] Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie
  • [ISO-abbreviation] Rom J Morphol Embryol
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Romania
  •  go-up   go-down


44. Fulmes M, Setrakian S, Raj PK, Bogard BM: Cancer biology and necrotic changes in metastatic lymph nodes and survival of colon cancer patients. Am J Surg; 2005 Mar;189(3):364-8
Genetic Alliance. consumer health - Metastatic cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cancer biology and necrotic changes in metastatic lymph nodes and survival of colon cancer patients.
  • BACKGROUND: Identifying factors that can contribute to a better understanding of tumor progression in stage III colon cancer patients continues to be an important task.
  • METHODS: The study included 48 consecutive colon and rectosigmoid cancer patients with stage III disease who underwent radical surgery.
  • [MeSH-major] Adenocarcinoma / mortality. Adenocarcinoma / pathology. Colonic Neoplasms / mortality. Colonic Neoplasms / pathology. Lymph Nodes / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15792771.001).
  • [ISSN] 0002-9610
  • [Journal-full-title] American journal of surgery
  • [ISO-abbreviation] Am. J. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


45. Fang YJ, Lu ZH, Wang F, Wu XJ, Li LR, Zhang LY, Pan ZZ, Wan DS: Prognostic impact of ERβ and MMP7 expression on overall survival in colon cancer. Tumour Biol; 2010 Dec;31(6):651-8
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic impact of ERβ and MMP7 expression on overall survival in colon cancer.
  • Estrogen receptor beta (ERβ) is the most highly expressed protein in patients with colon cancer.
  • We have previously shown that endocrine therapy can inhibit MMP7 expression in colon cancer cells.
  • In this study, we aim to identify the prognostic effects and correlation of ERβ and MMP7 in the context of colon cancer.
  • ERβ and MMP7 levels were assessed by immunohistochemistry in normal mucosa and tumoral tissues from 423 patients with stage I-III colon cancer.
  • In the subset of patients with high expression levels of tumoral nuclear ERβ, high expression of MMP7 was related to OS and CSS among colon cancer patients with high expression of ERβ.
  • In conclusion, our results suggest that low expression of ERβ was a risk factor in colon cancer, and high expression of MMP7 was an independent prognostic factor of ERβ-positive patients with colon cancer.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenocarcinoma / mortality. Colonic Neoplasms / metabolism. Colonic Neoplasms / mortality. Estrogen Receptor beta / metabolism. Matrix Metalloproteinase 7 / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20680712.001).
  • [ISSN] 1423-0380
  • [Journal-full-title] Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine
  • [ISO-abbreviation] Tumour Biol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Estrogen Receptor beta; EC 3.4.24.23 / Matrix Metalloproteinase 7
  •  go-up   go-down


46. Jestin P, Påhlman L, Glimelius B, Gunnarsson U: Cancer staging and survival in colon cancer is dependent on the quality of the pathologists' specimen examination. Eur J Cancer; 2005 Sep;41(14):2071-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cancer staging and survival in colon cancer is dependent on the quality of the pathologists' specimen examination.
  • Correct staging of colon cancer is decisive regarding further oncological treatment, surveillance and prediction of long-term survival.
  • Data from the colon cancer register (1997-2002) of the Uppsala/Orebro, Sweden, health care region were analysed and the seven pathology departments in this region were compared.
  • Included were 3735 patients who had undergone resection of a colon cancer.
  • Survival in stage II was lower when fewer than 12 nodes were examined or when the number of nodes sampled was not given (P = 0.001, log-rank test).
  • In stage III, those with at the most 3 nodes positive (N1) had a better survival than those with 4 or more nodes positive (N2) (P < 0.001, log-rank test).
  • An index of metastases (IM), derived from the number of nodes with metastases divided by the number of nodes examined, was calculated for stage III tumours.
  • Examination of 12 nodes is necessary to assure stage III cases with the median IM (0.32), whereas 20 nodes are necessary to assure 90% of cases with the lower quartile of IM (0.16).
  • The prognostic information of the IM was higher than that of the N-stage.
  • An index of metastases (IM) is a possible basis for guidance in the choice of adjuvant treatments that appears superior to that of N-stage.
  • [MeSH-major] Adenocarcinoma / pathology. Colonic Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16125926.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


47. Mammen JM, James LE, Molloy M, Williams A, Wray CJ, Sussman JJ: The relationship of lymph node dissection and colon cancer survival in the Veterans Affairs Central Cancer Registry. Am J Surg; 2007 Sep;194(3):349-54
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The relationship of lymph node dissection and colon cancer survival in the Veterans Affairs Central Cancer Registry.
  • BACKGROUND: The extent of lymphadenectomy in colon cancer may impact potential to cure and accuracy of staging.
  • METHODS: The Veterans Affairs Central Cancer Registry database was queried for TNM stage I-III colon adenocarcinoma patients and yielded 5,823 individuals.
  • RESULTS: The overall survival (OS) in stage II patients was greater with the higher number of lymph node (LN) examined.
  • For stage II patients, the 5-year OS was 34%, 43%, 47%, and 55% for the lowest to highest quartiles (P = .007).
  • For stage III patients, the 5-year OS was 31%, 27%, 38%, and 53% for the lowest to highest quartiles (not significant overall).
  • CONCLUSIONS: More extensive lymphadenectomy is associated with improved OS in stage II colon cancer patients.
  • [MeSH-major] Adenocarcinoma / mortality. Adenocarcinoma / surgery. Colonic Neoplasms / mortality. Colonic Neoplasms / surgery. Lymph Node Excision

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17693281.001).
  • [ISSN] 1879-1883
  • [Journal-full-title] American journal of surgery
  • [ISO-abbreviation] Am. J. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


48. Viehl CT, Ochsner A, von Holzen U, Cecini R, Langer I, Guller U, Laffer U, Oertli D, Zuber M: Inadequate quality of surveillance after curative surgery for colon cancer. Ann Surg Oncol; 2010 Oct;17(10):2663-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inadequate quality of surveillance after curative surgery for colon cancer.
  • BACKGROUND: Colon cancer patients are at risk for recurrence.
  • The objective of this study is to analyze the quality of surveillance after curative surgery for colon cancer among a cohort of Swiss patients.
  • PATIENTS AND METHODS: After curative surgery, 129 stage I-III colon cancer patients were followed by chart review, questionnaires, and phone interviews.
  • CONCLUSIONS: The quality of surveillance after curative surgery for colon cancer among a cohort of Swiss patients is inadequate.
  • [MeSH-major] Adenocarcinoma / surgery. Colonic Neoplasms / surgery. Continuity of Patient Care

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20429036.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carcinoembryonic Antigen
  •  go-up   go-down


49. Fishman DA, Cohen L, Blank SV, Shulman L, Singh D, Bozorgi K, Tamura R, Timor-Tritsch I, Schwartz PE: The role of ultrasound evaluation in the detection of early-stage epithelial ovarian cancer. Am J Obstet Gynecol; 2005 Apr;192(4):1214-21; discussion 1221-2
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of ultrasound evaluation in the detection of early-stage epithelial ovarian cancer.
  • OBJECTIVE: Epithelial ovarian cancer kills more women than all other gynecologic malignancies combined because of our inability to detect early-stage disease.
  • Ultrasonography has demonstrated usefulness in the detection of ovarian cancer in asymptomatic women, but its value for the detection of early-stage epithelial ovarian cancer in women of increased risk is uncertain.
  • We examined the usefulness of sonography in the detection of early-stage epithelial ovarian cancer in asymptomatic high-risk women who participated in the National Ovarian Cancer Early Detection Program.
  • Increased risk includes women with at least 1 affected first-degree relative with ovarian cancer; a personal history of breast, ovarian, or colon cancer; > or =1 affected first- and second-degree relatives with breast and or ovarian cancer; inheritance of a breast cancer mutation from an affected family member, or membership within a recognized cancer syndrome.
  • The detected malignancies were fallopian tube carcinoma (stage IIIC; n = 4 women), primary peritoneal carcinoma (n = 4 women; stage IIIA, 1 woman; stage IIIB, 2 women; stage IIIC, 1 woman), epithelial ovarian cancer (stages IIIA and IIIB; n = 2 women), and endometrial adenocarcinoma (stage IA; n = 2 women).
  • A total of 184 women with genetic predisposition (breast cancer positive) have undergone a prophylactic bilateral salpingo-oophorectomy; 23% of these procedures found atypical hyperplasia, and unexpectedly, 2 women (1%) were found to have stage III (A and B) primary peritoneal carcinoma.
  • CONCLUSION: This study demonstrates the limited value of diagnostic ultrasound examination as an independent modality for the detection of early-stage epithelial ovarian cancer in asymptomatic women who are at increased risk for disease.

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15846205.001).
  • [ISSN] 0002-9378
  • [Journal-full-title] American journal of obstetrics and gynecology
  • [ISO-abbreviation] Am. J. Obstet. Gynecol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P50 CA83639; United States / NCI NIH HHS / CA / R01 CA01015; United States / NCI NIH HHS / CA / R01 CA82562; United States / NCI NIH HHS / CA / R01 CA89503; United States / NCI NIH HHS / CA / UO1CA85133
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


50. Sinicrope FA, Rego RL, Foster N, Sargent DJ, Windschitl HE, Burgart LJ, Witzig TE, Thibodeau SN: Microsatellite instability accounts for tumor site-related differences in clinicopathologic variables and prognosis in human colon cancers. Am J Gastroenterol; 2006 Dec;101(12):2818-25
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Microsatellite instability accounts for tumor site-related differences in clinicopathologic variables and prognosis in human colon cancers.
  • OBJECTIVE: Colon cancers with high frequency microsatellite instability (MSI-H) are preferentially located in the proximal colon.
  • Given that 15-20% of sporadic colon cancers are MSI-H, we determined whether tumor site-specific differences in clinicopathological variables, biomarkers, and prognosis are due to inclusion of MSI-H cases.
  • METHODS: TNM stage II and III primary colon carcinomas (N = 528) from patients enrolled in 5-fluorouracil-based adjuvant trials were analyzed for MSI using 11 microsatellite markers.
  • RESULTS: MSI-H was found in 95 (18%) colon cancers.
  • CONCLUSIONS: Tumor site-related differences in clinicopathological variables, biomarkers, and prognosis of sporadic colon cancers can be explained by the inclusion of MSI-H cases.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17026563.001).
  • [ISSN] 0002-9270
  • [Journal-full-title] The American journal of gastroenterology
  • [ISO-abbreviation] Am. J. Gastroenterol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U01 CA074800; United States / NCI NIH HHS / CA / CA 104683
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Carrier Proteins; 0 / DNA-Binding Proteins; 0 / G-T mismatch-binding protein; 0 / MLH1 protein, human; 0 / Nuclear Proteins; 0 / Tumor Suppressor Protein p53; EC 3.6.1.3 / MSH2 protein, human; EC 3.6.1.3 / MutS Homolog 2 Protein
  •  go-up   go-down


51. Berger AC, Sigurdson ER, LeVoyer T, Hanlon A, Mayer RJ, Macdonald JS, Catalano PJ, Haller DG: Colon cancer survival is associated with decreasing ratio of metastatic to examined lymph nodes. J Clin Oncol; 2005 Dec 1;23(34):8706-12
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Colon cancer survival is associated with decreasing ratio of metastatic to examined lymph nodes.
  • PATIENTS AND METHODS: We analyzed data from Intergroup trial 0089 of adjuvant chemotherapy for stage II and III patients with colon cancer, in which all patients received fluorouracil-based therapy.
  • Covariates included in the models were age, sex, tumor stage, grade, histology, number of positive LNs, number of LNs removed, and LNR.
  • [MeSH-major] Adenocarcinoma / therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Colonic Neoplasms / therapy. Lymphatic Metastasis / pathology

  • Genetic Alliance. consumer health - Metastatic cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16314630.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


52. Fazeli MS, Adel MG, Lebaschi AH: Colorectal carcinoma: a retrospective, descriptive study of age, gender, subsite, stage, and differentiation in Iran from 1995 to 2001 as observed in Tehran University. Dis Colon Rectum; 2007 Jul;50(7):990-5
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Colorectal carcinoma: a retrospective, descriptive study of age, gender, subsite, stage, and differentiation in Iran from 1995 to 2001 as observed in Tehran University.
  • These factors also are evaluated in conjunction with disease stage and tumor differentiation at the time of diagnosis.
  • METHODS: Data from 419 patients from a population that receives no screening between April 1995 and March 2001 operated on in the Cancer Institute and Imam Khomieni Hospital with a diagnosis of colorectal cancer were used to describe distribution of the colorectal carcinoma by age, gender, tumor subsite and pathology, and stage at diagnosis.
  • RESULTS: There were 403 (96.2 percent) cases of adenocarcinoma.
  • Patients were divided into two age groups (40 years and younger, and older than 40 years); 16.4 percent of patients had tumors in the proximal colon and 83.6 percent in distal parts.
  • Most patients were Stage II and III (48.1 and 33.4 percent, respectively).
  • Most patients in the younger age group were Stage III (45 percent) and in the older age group were Stage II (53.2 percent; P<0.001).
  • There were no differences in stage and tumor differentiation between two genders, but most of the patients with tumors in proximal colon were males (62.5 percent; P=0.1).
  • [MeSH-major] Adenocarcinoma / epidemiology. Adenocarcinoma / pathology. Colorectal Neoplasms / epidemiology. Colorectal Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17525859.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


53. Xie L, Villeneuve PJ, Shaw A: Survival of patients diagnosed with either colorectal mucinous or non-mucinous adenocarcinoma: a population-based study in Canada. Int J Oncol; 2009 Apr;34(4):1109-15
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival of patients diagnosed with either colorectal mucinous or non-mucinous adenocarcinoma: a population-based study in Canada.
  • Previous studies have shown conflicting results on the prognosis of colorectal mucinous adenocarcinoma.
  • Analyses were based on 165 colorectal mucinous and 1215 non-mucinous adenocarcinoma patients who were registered at the Ottawa Regional Cancer Centre from 1994 to 1997, with follow-up extending to December 31, 2001.
  • For colon, rectum and both combined, the distribution for age at diagnosis, stage and treatment of patients with mucinous adenocarcinoma was similar to that of non-mucinous patients (all p > or = 0.12).
  • Overall, no statistically significant differences were noted in 5-year relative survival between mucinous and non-mucinous carcinoma for colon, rectum and their combination (p > or = 0.35 for each).
  • However, when the stages were considered separately, patients with stage III mucinous carcinoma had worse survival than patients with non-mucinous carcinoma for both sites.
  • Multivariate analysis of combined data for colon and rectal cancers indicated that independent significant prognostic factors were stage for mucinous, with age and grade as well as stage for non-mucinous carcinoma.
  • In conclusion, no significant differences in stage distribution and overall survival were found between mucinous and non-mucinous patients for colorectal cancer.
  • [MeSH-major] Adenocarcinoma / mortality. Adenocarcinoma, Mucinous / mortality. Colorectal Neoplasms / mortality

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19287969.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


54. Barrier A, Lemoine A, Boelle PY, Tse C, Brault D, Chiappini F, Breittschneider J, Lacaine F, Houry S, Huguier M, Van der Laan MJ, Speed T, Debuire B, Flahault A, Dudoit S: Colon cancer prognosis prediction by gene expression profiling. Oncogene; 2005 Sep 8;24(40):6155-64
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Colon cancer prognosis prediction by gene expression profiling.
  • This study assessed the possibility to build a prognosis predictor, based on microarray gene expression measures, in stage II and III colon cancer patients.
  • This study suggests that one can build an accurate prognosis predictor for stage II and III colon cancer patients, based on gene expression measures, and one can use either tumour or non-neoplastic mucosa for this purpose.
  • [MeSH-major] Adenocarcinoma / genetics. Adenocarcinoma / secondary. Colonic Neoplasms / genetics. Colonic Neoplasms / pathology. Gene Expression Profiling. Genetic Markers. Oligonucleotide Array Sequence Analysis

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16091735.001).
  • [ISSN] 0950-9232
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Genetic Markers
  •  go-up   go-down


55. Kornmann M, Formentini A, Ette C, Henne-Bruns D, Kron M, Sander S, Baumann W, Kreuser ED, Staib L, Link KH: Prognostic factors influencing the survival of patients with colon cancer receiving adjuvant 5-FU treatment. Eur J Surg Oncol; 2008 Dec;34(12):1316-21
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors influencing the survival of patients with colon cancer receiving adjuvant 5-FU treatment.
  • AIM: Adjuvant chemotherapy is recommended for stage III colon cancer.
  • The aim of this study was to identify important prognostic factors among patients with colon cancer receiving adjuvant 5-FU-based treatment.
  • METHODS: Data sets of 855 colon cancer patients treated between 1992 and 1999 within a multicenter adjuvant trial comparing 5-FU modulation with folinic acid or interfereron-alpha were examined.
  • In the future, this may result in adjuvant treatment of stage III colon cancer adjusted for the risk of substages.
  • [MeSH-major] Adenocarcinoma / mortality. Antimetabolites, Antineoplastic / therapeutic use. Colonic Neoplasms / mortality. Fluorouracil / therapeutic use

  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18313881.001).
  • [ISSN] 1532-2157
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Immunologic Factors; 0 / Interferon-alpha; 12001-76-2 / Vitamin B Complex; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


56. Kabra N, Li Z, Chen L, Li B, Zhang X, Wang C, Yeatman T, Coppola D, Chen J: SirT1 is an inhibitor of proliferation and tumor formation in colon cancer. J Biol Chem; 2009 Jul 3;284(27):18210-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] SirT1 is an inhibitor of proliferation and tumor formation in colon cancer.
  • Immunohistochemical staining revealed high level SirT1 in normal colon mucosa and benign adenomas.
  • SirT1 overexpression was observed in approximately 25% of stage I/II/III colorectal adenocarcinomas but rarely found in advanced stage IV tumors.
  • These results suggest a rationale for the use of SirT1 activators and inhibitors in the prevention and treatment of colon cancer.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 2000 Feb 17;403(6771):795-800 [10693811.001]
  • [Cites] Science. 2000 Sep 22;289(5487):2126-8 [11000115.001]
  • [Cites] Nature. 2001 Mar 8;410(6825):227-30 [11242085.001]
  • [Cites] Cell. 2001 Oct 19;107(2):137-48 [11672522.001]
  • [Cites] Cell. 2001 Oct 19;107(2):149-59 [11672523.001]
  • [Cites] Nature. 2003 Sep 11;425(6954):191-6 [12939617.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Sep 16;100(19):10794-9 [12960381.001]
  • [Cites] Cell. 2004 Feb 20;116(4):551-63 [14980222.001]
  • [Cites] EMBO J. 2004 Jun 16;23(12):2369-80 [15152190.001]
  • [Cites] Science. 2004 Jul 16;305(5682):390-2 [15205477.001]
  • [Cites] Science. 1990 Jan 19;247(4940):322-4 [2296722.001]
  • [Cites] Cancer Res. 1994 Nov 15;54(22):5947-52 [7954427.001]
  • [Cites] Nature. 2005 Mar 3;434(7029):113-8 [15744310.001]
  • [Cites] Cell Metab. 2005 Jul;2(1):67-76 [16054100.001]
  • [Cites] Cell Metab. 2005 Aug;2(2):105-17 [16098828.001]
  • [Cites] Cell. 2005 Nov 4;123(3):437-48 [16269335.001]
  • [Cites] Cancer Res. 2005 Nov 15;65(22):10457-63 [16288037.001]
  • [Cites] Mol Cell Biol. 2006 Jan;26(1):28-38 [16354677.001]
  • [Cites] Oncogene. 2006 Jan 12;25(2):176-85 [16170353.001]
  • [Cites] PLoS Biol. 2006 Feb;4(2):e31 [16366736.001]
  • [Cites] Cancer Res. 2006 Apr 15;66(8):4368-77 [16618762.001]
  • [Cites] Nat Cell Biol. 2006 Sep;8(9):1025-31 [16892051.001]
  • [Cites] Mol Cell Biol. 2006 Nov;26(21):8122-35 [16923962.001]
  • [Cites] Nature. 2006 Nov 16;444(7117):337-42 [17086191.001]
  • [Cites] Cell. 2006 Dec 15;127(6):1109-22 [17112576.001]
  • [Cites] Mol Cell. 2007 Feb 23;25(4):543-57 [17317627.001]
  • [Cites] Arch Dermatol Res. 2007 May;299(2):103-6 [17180656.001]
  • [Cites] Mol Cell. 2007 Jul 6;27(1):149-62 [17612497.001]
  • [Cites] Cancer Res. 2007 Jul 15;67(14):6612-8 [17638871.001]
  • [Cites] Oncogene. 2007 Aug 13;26(37):5489-504 [17694089.001]
  • [Cites] Biochem J. 2007 Nov 1;407(3):451-60 [17620057.001]
  • [Cites] Biotechnol J. 2007 Nov;2(11):1360-8 [17806102.001]
  • [Cites] Nature. 2007 Nov 29;450(7170):712-6 [18046409.001]
  • [Cites] Mol Biol Cell. 2008 Mar;19(3):1210-9 [18184747.001]
  • [Cites] PLoS One. 2008;3(4):e2020 [18414679.001]
  • [Cites] Cancer Cell. 2008 Oct 7;14(4):312-23 [18835033.001]
  • (PMID = 19433578.001).
  • [ISSN] 1083-351X
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA112215; United States / NCI NIH HHS / CA / R01 CA112215-03; United States / NCI NIH HHS / CA / CA121291; United States / NCI NIH HHS / CA / R01 CA121291; United States / NCI NIH HHS / CA / CA112215-03
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / RNA, Small Interfering; EC 3.5.1.- / SIRT1 protein, human; EC 3.5.1.- / Sirtuin 1; EC 3.5.1.- / Sirtuins; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ PMC2709385
  •  go-up   go-down


57. Rego RL, Foster NR, Smyrk TC, Le M, O'Connell MJ, Sargent DJ, Windschitl H, Sinicrope FA: Prognostic effect of activated EGFR expression in human colon carcinomas: comparison with EGFR status. Br J Cancer; 2010 Jan 5;102(1):165-72
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic effect of activated EGFR expression in human colon carcinomas: comparison with EGFR status.
  • BACKGROUND: Evidence suggests that epidermal growth factor receptor (EGFR)-activation status may better predict the clinical behaviour of colon cancers than does EGFR expression.
  • However, the prognostic effect of phospho-EGFR in primary colon cancer remains undefined.
  • METHODS: Phospho-EGFR (Tyr-1173) and EGFR expression were analysed by immunohistochemistry (IHC) in tissue microarrays of TNM stage II and III colon cancers from completed adjuvant therapy trials (n=388).
  • Although phospho-EGFR was unrelated to clinicopathological variables, strong EGFR intensity was associated with higher tumour stage (P=0.03).
  • Stage and lymph node number were prognostic for DFS and OS, and histological grade for OS.
  • EGFR was an independent predictor of DFS (P=0.042) after adjustment for stage, histological grade, age, and MMR status.

  • COS Scholar Universe. author profiles.
  • PhosphoSitePlus. gene/protein/disease-specific - PhosphoSitePlus® - comprehensive post-translational modification resource .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2004 May 1;22(9):1572-82 [15117979.001]
  • [Cites] Mol Cell Biol. 2003 Nov;23(21):7875-86 [14560030.001]
  • [Cites] N Engl J Med. 2004 May 20;350(21):2129-39 [15118073.001]
  • [Cites] Science. 2004 Jun 4;304(5676):1497-500 [15118125.001]
  • [Cites] Clin Cancer Res. 2004 Oct 1;10(19):6487-501 [15475436.001]
  • [Cites] Science. 1993 May 7;260(5109):816-9 [8484122.001]
  • [Cites] Cancer Res. 1993 Dec 15;53(24):5849-52 [8261392.001]
  • [Cites] J Biol Chem. 1994 Jul 15;269(28):18674-8 [8034616.001]
  • [Cites] Eur J Surg Oncol. 1995 Jun;21(3):269-75 [7781795.001]
  • [Cites] Biochemistry. 1995 Dec 19;34(50):16456-66 [8845374.001]
  • [Cites] Gastroenterology. 1996 Mar;110(3):669-74 [8608874.001]
  • [Cites] Cancer Res. 1998 Apr 15;58(8):1713-8 [9563488.001]
  • [Cites] Clin Cancer Res. 1995 Jan;1(1):19-31 [9815883.001]
  • [Cites] Cancer Res. 1998 Nov 15;58(22):5248-57 [9823339.001]
  • [Cites] J Natl Cancer Inst. 1999 Aug 4;91(15):1295-303 [10433618.001]
  • [Cites] J Biol Chem. 1999 Sep 10;274(37):26091-7 [10473558.001]
  • [Cites] Ann Oncol. 2005 Jan;16(1):102-8 [15598946.001]
  • [Cites] J Clin Oncol. 2005 Mar 20;23(9):1803-10 [15677699.001]
  • [Cites] Int J Oncol. 2005 Aug;27(2):317-25 [16010411.001]
  • [Cites] Mod Pathol. 2005 Oct;18(10):1350-6 [15832190.001]
  • [Cites] Semin Oncol. 2005 Dec;32(6 Suppl 9):S59-62 [16399434.001]
  • [Cites] J Clin Oncol. 2006 Mar 1;24(7):1169-77 [16505437.001]
  • [Cites] Cancer Res. 2006 Mar 1;66(5):2834-43 [16510606.001]
  • [Cites] Clin Cancer Res. 2006 May 1;12(9):2738-44 [16675565.001]
  • [Cites] Clin Colorectal Cancer. 2006 Jul;6(2):133-9 [16945169.001]
  • [Cites] Gastroenterology. 2006 Sep;131(3):729-37 [16952542.001]
  • [Cites] Br J Cancer. 2006 Dec 4;95(11):1525-8 [17088913.001]
  • [Cites] Int J Cancer. 2007 Mar 15;120(6):1232-8 [17187355.001]
  • [Cites] Lung Cancer. 2007 Mar;55(3):349-55 [17161498.001]
  • [Cites] J Clin Oncol. 2007 May 1;25(13):1658-64 [17470858.001]
  • [Cites] J Clin Oncol. 2007 Jun 1;25(16):2184-90 [17538163.001]
  • [Cites] Clin Cancer Res. 2007 Jun 15;13(12):3597-604 [17575224.001]
  • [Cites] J Clin Oncol. 2007 Oct 1;25(28):4405-13 [17906204.001]
  • [Cites] Ann Oncol. 2008 Dec;19(12):2033-8 [18632722.001]
  • [Cites] Pathology. 2009;41(4):356-60 [19404848.001]
  • [Cites] Curr Opin Oncol. 2009 Jul;21(4):369-73 [19444104.001]
  • [Cites] Clin Cancer Res. 2009 Jul 15;15(14):4531-7 [19584170.001]
  • [Cites] N Engl J Med. 2000 Jan 13;342(2):69-77 [10631274.001]
  • [Cites] Cancer. 2000 Apr 1;88(7):1739-57 [10738234.001]
  • [Cites] Cancer Res. 2000 Apr 15;60(8):2225-31 [10786688.001]
  • [Cites] Int J Cancer. 2000 Oct 1;88(1):77-81 [10964085.001]
  • [Cites] Nat Rev Mol Cell Biol. 2001 Feb;2(2):127-37 [11252954.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Feb 5;99(3):1521-6 [11818567.001]
  • [Cites] J Clin Oncol. 2002 Apr 1;20(7):1735-43 [11919229.001]
  • [Cites] Clin Cancer Res. 2002 Apr;8(4):945-54 [11948098.001]
  • [Cites] Eur J Cancer. 2002 May;38(8):1065-71 [12008194.001]
  • [Cites] Eur J Cancer. 2002 Nov;38(17):2258-64 [12441262.001]
  • [Cites] Eur J Cancer. 2003 Jul;39(10):1348-54 [12826036.001]
  • [Cites] N Engl J Med. 2003 Jul 17;349(3):247-57 [12867608.001]
  • [Cites] Virchows Arch. 2003 Aug;443(2):115-21 [12802583.001]
  • [Cites] Clin Cancer Res. 2004 May 1;10(9):3069-75 [15131045.001]
  • (PMID = 19997103.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / P30 DK084567; United States / NCI NIH HHS / CA / R01 CA104683; United States / NCI NIH HHS / CA / CA 104683
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 21820-51-9 / Phosphotyrosine; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ PMC2813748
  •  go-up   go-down


58. Kim ST, Lee J, Park SH, Park JO, Lim HY, Kang WK, Kim JY, Kim YH, Chang DK, Rhee PL, Kim DS, Yun H, Cho YB, Kim HC, Yun SH, Lee WY, Chun HK, Park YS: Clinical impact of microsatellite instability in colon cancer following adjuvant FOLFOX therapy. Cancer Chemother Pharmacol; 2010 Sep;66(4):659-67
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical impact of microsatellite instability in colon cancer following adjuvant FOLFOX therapy.
  • PURPOSE: Colon cancer with DNA mismatch repair (MMR) defects reveals indistinguishable clinical and pathologic aspects, including better prognosis and reduced response to 5-fluorouracil (5-FU)-based chemotherapy.
  • This study investigated the clinical implication of MSI-H/MMR-D and p53 expression in R0-resected colon cancer patients who received adjuvant oxaliplatin/5-FU/leucovorin (FOLFOX) therapy.
  • EXPERIMENTAL DESIGN: We analyzed 135 patients, who had been treated by adjuvant chemotherapy containing 5-FU and oxaliplatin (FOLFOX) after curative resection (R0) for colon adenocarcinoma between May 2004 and November 2007.
  • RESULTS: There were 13 (9.6%) patients with stage II, 108 (80%) with stage III, and 14 (10.4%) with stage IV.
  • Fourteen patients with stage IV (10.3%) had metastases to liver only, all of whom underwent complete metastasectomy for liver metastases.
  • MMR status was not significantly associated with DFS (P = 0.56) or OS (P = 0.61) in patients with colon cancer (n = 135) receiving adjuvant FOLFOX.
  • CONCLUSION: The MMR status or p53 positivity was not significantly associated with outcomes to FOLFOX as adjuvant chemotherapy in colon cancer patients with R0 resection.
  • Adding oxaliplatin in adjuvant chemotherapy may overcome negative impact of 5-FU on colon cancers with MSI-H/MMR-D.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / genetics. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Colonic Neoplasms / drug therapy. Colonic Neoplasms / genetics. Microsatellite Instability / drug effects

  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20033812.001).
  • [ISSN] 1432-0843
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Genetic Markers; 0 / Organoplatinum Compounds; 0 / Tumor Suppressor Protein p53; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; Folfox protocol
  •  go-up   go-down


59. Liang JT, Lai HS, Lee PH, Chang KJ: Laparoscopic pelvic autonomic nerve-preserving surgery for sigmoid colon cancer. Ann Surg Oncol; 2008 Jun;15(6):1609-16

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopic pelvic autonomic nerve-preserving surgery for sigmoid colon cancer.
  • BACKGROUND: To test the feasibility of laparoscopic approach in performing the simultaneous pelvic autonomic nerve preservation during standard anterior resection of sigmoid colon cancer.
  • RESULTS: A total of 112 patients (tumor, node, metastasis system stage I, n = 8; stage II, n = 54; stage III, n = 50; male, n = 58; female, n = 54; age [mean +/- standard deviation], 55.8 +/- 6.4 years) with good baseline genitourinary function were operated on with the intent of total preservation of pelvic autonomic nerves and curative resection of sigmoid colon cancer.
  • CONCLUSIONS: Under laparoscopy, we can clearly identify and preserve the pelvic autonomic nerves to retain genitourinary function in most patients undergoing oncologic resection of sigmoid colon cancer.
  • [MeSH-major] Adenocarcinoma / surgery. Autonomic Pathways / surgery. Colectomy. Sigmoid Neoplasms / surgery. Trauma, Nervous System / prevention & control

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Surg. 2004 Apr;91(4):465-8 [15048749.001]
  • [Cites] Tech Coloproctol. 2003 Apr;7(1):29-33 [12750952.001]
  • [Cites] Dis Colon Rectum. 2005 Dec;48(12):2354-61 [16408331.001]
  • [Cites] Br J Surg. 2005 Nov;92(11):1444-8 [16184622.001]
  • [Cites] Br J Surg. 2005 Sep;92(9):1124-32 [15997446.001]
  • [Cites] Ann Surg. 2005 Aug;242(2):212-23 [16041212.001]
  • [Cites] World J Surg. 2003 Feb;27(2):190-6 [12616435.001]
  • [Cites] Dis Colon Rectum. 2002 Sep;45(9):1178-85 [12352233.001]
  • [Cites] J Sex Marital Ther. 2000 Apr-Jun;26(2):191-208 [10782451.001]
  • [Cites] Semin Surg Oncol. 2000 Apr-May;18(3):235-43 [10757889.001]
  • [Cites] Hepatogastroenterology. 2004 Sep-Oct;51(59):1354-7 [15362751.001]
  • [Cites] Hepatogastroenterology. 1998 Nov-Dec;45(24):2206-14 [9951896.001]
  • [Cites] Ann Surg Oncol. 2007 Apr;14(4):1285-7 [17235719.001]
  • [Cites] Ann Surg Oncol. 2007 Jan;14(1):109-17 [17066227.001]
  • [Cites] Int J Clin Oncol. 2006 Oct;11(5):339-43 [17058130.001]
  • [Cites] Dis Colon Rectum. 2004 Sep;47(9):1442-7 [15486739.001]
  • [Cites] Ann Surg. 1988 Oct;208(4):391-400 [3178328.001]
  • [Cites] Dis Colon Rectum. 1995 Nov;38(11):1162-8 [7587758.001]
  • [Cites] Cancer. 1996 Nov 1;78(9):1871-80 [8909305.001]
  • [Cites] Br J Surg. 1997 Apr;84(4):586-7 [9112939.001]
  • [Cites] Urology. 1997 Jun;49(6):822-30 [9187685.001]
  • [Cites] Br J Surg. 1998 Aug;85(8):1162 [9718031.001]
  • (PMID = 18365285.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2373867
  •  go-up   go-down


60. Scheiden R, Pescatore P, Wagener Y, Kieffer N, Capesius C: Colon cancer in Luxembourg: a national population-based data report, 1988-1998. BMC Cancer; 2005;5:52

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Colon cancer in Luxembourg: a national population-based data report, 1988-1998.
  • BACKGROUND: Over the last two decades time trends in incidence rates of colorectal cancer, changes in the proportions of stage at diagnosis and changes in the anatomic sub-site distribution of colon cancers have been reported in some European countries.
  • In order to determine a strategy for early detection of colon cancer in the Grand-Duchy of Luxembourg, all consecutive colon adenocarcinomas diagnosed during the period 1988-1998 at a nation-wide level were reviewed.
  • METHODS: The population-based data of the national Morphologic Tumour Registry report all new high-grade adenomas (i.e. high-grade intraepithelial adenomatous neoplasias) and all consecutive new invasive adenocarcinomas of the colon diagnosed in the central department of pathology.
  • Attention has been focused on variations in incidence, stage, anatomical site distribution and survival rates.
  • RESULTS: Over the study period, 254 new colonic high-grade adenomas and 1379 new invasive adenocarcinomas were found; the crude incidence rates of colon adenocarcinomas grew steadily by 30%.
  • Comparing the two 5-year periods 1988-1992 and 1994-1998, the crude incidence rates of high-grade adenomas (stage 0) rose by 190%, that of stage I cases by 14.3%, stage II cases 12.9% and stage III cases 38.5%, whereas the crude incidence rates of stage IV cases decreased by 11.8%.
  • The high-grade adenoma/adenocarcinoma ratio increased.
  • The overall observed 5-year survival rate (stage I-IV) was 51 +/- 3% (95% confidence interval).
  • CONCLUSION: The increasing incidence rates of colon adenocarcinomas, the persistence of advanced tumour stages (stage III), the mortality rates which remain stable, and the changing trends in the age- and sub-site distribution underline the need for preventive measures at the age of 50 in asymptomatic patients to reduce mortality from colo(rectal) cancer.
  • [MeSH-major] Adenocarcinoma / epidemiology. Colonic Neoplasms / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Med. 2001 Dec 1;111(8):593-601 [11755501.001]
  • [Cites] Cancer. 2001 Nov 15;92(10):2547-54 [11745188.001]
  • [Cites] Oncologist. 2002;7(3):200-4 [12065791.001]
  • [Cites] Gut. 2002 Jul;51(1):60-4 [12077093.001]
  • [Cites] Int J Cancer. 2002 Oct 10;101(5):403-8 [12216066.001]
  • [Cites] Dis Colon Rectum. 2002 Sep;45(9):1249-54 [12352244.001]
  • [Cites] Am Surg. 2002 Oct;68(10):871-6 [12412713.001]
  • [Cites] Eur J Cancer Prev. 2002 Dec;11(6):529-34 [12457104.001]
  • [Cites] Gastroenterology. 2003 Feb;124(2):544-60 [12557158.001]
  • [Cites] Jpn J Clin Oncol. 2003 Jan;33(1):38-43 [12604723.001]
  • [Cites] Scand J Surg. 2003;92(1):5-9 [12705545.001]
  • [Cites] An Sist Sanit Navar. 2003 Jan-Apr;26(1):79-97 [12759713.001]
  • [Cites] N Z Med J. 2003 May 16;116(1174):U437 [12766783.001]
  • [Cites] Surg Endosc. 2003 Jun;17(6):886-90 [12658426.001]
  • [Cites] Dis Colon Rectum. 2003 Oct;46(10 Suppl):S32-43 [14530656.001]
  • [Cites] Am Surg. 2003 Oct;69(10):866-72 [14570365.001]
  • [Cites] Dig Dis. 2003;21(4):315-9 [14752221.001]
  • [Cites] W V Med J. 2003 Sep-Oct;99(5):182-6 [14959509.001]
  • [Cites] Int J Cancer. 2004 May 1;109(5):777-81 [14999789.001]
  • [Cites] Am Surg. 2004 Mar;70(3):259-64 [15055851.001]
  • [Cites] BMC Cancer. 2003 Oct 21;3:27 [14567762.001]
  • [Cites] IARC Sci Publ. 1992;(120):178-861 [1284601.001]
  • [Cites] Semin Surg Oncol. 1994 Jan-Feb;10(1):12-20 [8115781.001]
  • [Cites] N Engl J Med. 2002 Jun 6;346(23):1781-5 [12050337.001]
  • (PMID = 15913456.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1173094
  •  go-up   go-down


61. Angitapalli R, Litwin AM, Kumar PR, Nasser E, Lombardo J, Mashtare T, Wilding GE, Fakih MG: Adjuvant FOLFOX chemotherapy and splenomegaly in patients with stages II-III colorectal cancer. Oncology; 2009;76(5):363-8
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant FOLFOX chemotherapy and splenomegaly in patients with stages II-III colorectal cancer.
  • BACKGROUND: The impact of adjuvant chemotherapy on hepatic function and portal hypertension in patients with stages II-III colon cancer has not been previously described.
  • METHODS: Stage II-III colorectal cancer patients treated with adjuvant FOLFOX or fluorouracil/leucovorin (5-FU/LV) at Roswell Park Cancer Institute between 2002 and 2006 were identified.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Colorectal Neoplasms / drug therapy. Splenomegaly / chemically induced

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Splenomegaly.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 S. Karger AG, Basel.
  • (PMID = 19321964.001).
  • [ISSN] 1423-0232
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; Folfox protocol
  •  go-up   go-down


62. Pasetto LM, Falci C, Basso U, Gasparini G, D'Andrea M, Bonginelli P, Bajetta E, Platania M, Alabiso O, Miraglia S, Bertona E, Oniga F, Biason R, Chetrì MC, Fedele P, Massara G, Romaniello I, Negru ME, Luchena G, Giordano M, Buzzi F, Ricottao R, Sienao S, Monfardini S: Adjuvant treatment for elderly patients with colon cancer. An observational study. Anticancer Res; 2008 Jul-Aug;28(4C):2513-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant treatment for elderly patients with colon cancer. An observational study.
  • BACKGROUND: Adjuvant 5-fluoruracil-based chemotherapy significantly reduces mortality in patients with stage II-III colon cancer, but is less prescribed with rising age.
  • PATIENTS AND METHODS: From January to December 2004, 63 questionnaires on the management of stage II-III resected colon cancer patients aged over 70 years, collected from 10 Italian Centres, were retrospectively examined.
  • Due to the paucity of events, the impact of prognostic factors (patient's age and comorbidity, tumour stage and grade) on DFS and OS could not be assessed.
  • CONCLUSION: An increasing proportion of elderly patients with colon cancer may be treated with a tolerability and OS similar to those observed in the younger population.
  • [MeSH-major] Adenocarcinoma / drug therapy. Colonic Neoplasms / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18751443.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] Greece
  •  go-up   go-down


63. Suh KW, Kim JH, Kim YB, Kim J, Jeong S: Thymidylate synthase gene polymorphism as a prognostic factor for colon cancer. J Gastrointest Surg; 2005 Mar;9(3):336-42

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thymidylate synthase gene polymorphism as a prognostic factor for colon cancer.
  • Here, we determined the significance of this polymorphism in predicting the clinical outcomes for patients with colon cancer.
  • We reviewed 121 consecutive patients with stage II or III colon cancer who underwent a curative resection.
  • The difference was particularly significant in the patients with stage III disease (41% versus 77%, P=0.0414).
  • Tumor stage and the TS polymorphism were identified as significant prognostic factors by multivariate analysis.
  • We found the TS polymorphism to be a significant and independent prognostic factor for colon cancer.
  • [MeSH-major] Adenocarcinoma / genetics. Adenocarcinoma / mortality. Biomarkers, Tumor / analysis. Colonic Neoplasms / genetics. Colonic Neoplasms / mortality. Thymidylate Synthase / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15749593.001).
  • [ISSN] 1091-255X
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 2.1.1.45 / Thymidylate Synthase
  •  go-up   go-down


64. Gönen M, Schrag D, Weiser MR: Nodal staging score: a tool to assess adequate staging of node-negative colon cancer. J Clin Oncol; 2009 Dec 20;27(36):6166-71
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nodal staging score: a tool to assess adequate staging of node-negative colon cancer.
  • PURPOSE: Adequate nodal staging of colon cancer has been defined as pathologic examination of at least 12 lymph nodes.
  • PATIENTS AND METHODS: Patients with stage I-III adenocarcinoma of the colon between 1994 and 2005 and had at least one lymph node pathologically examined were identified from the Surveillance, Epidemiology and End Results (SEER) database (n = 131,953).
  • NSS is a function of T stage and the number of examined nodes.
  • CONCLUSION: The minimum number of examined nodes for adequate staging depends on the T stage.
  • [MeSH-major] Adenocarcinoma / pathology. Colonic Neoplasms / pathology. Lymph Nodes / pathology. Models, Statistical

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1999 Sep;17(9):2896-900 [10561368.001]
  • [Cites] Colorectal Dis. 2010 Jan;12(1):44-7 [19438890.001]
  • [Cites] World J Surg. 2002 Mar;26(3):384-9 [11865379.001]
  • [Cites] Ann Surg. 2002 Apr;235(4):458-63 [11923600.001]
  • [Cites] Ann Surg Oncol. 2003 Jan-Feb;10(1):65-71 [12513963.001]
  • [Cites] Ann Surg Oncol. 2003 Apr;10(3):213-8 [12679304.001]
  • [Cites] J Clin Oncol. 2003 Aug 1;21(15):2912-9 [12885809.001]
  • [Cites] Ann Surg Oncol. 2003 Oct;10(8):903-9 [14527909.001]
  • [Cites] J Clin Oncol. 2004 Aug 15;22(16):3408-19 [15199089.001]
  • [Cites] Ann Surg. 2004 Oct;240(4):624-8; discussion 628-30 [15383790.001]
  • [Cites] J Ky Med Assoc. 2004 Aug;102(8):345-7 [15384384.001]
  • [Cites] Am J Clin Pathol. 1996 Aug;106(2):209-16 [8712176.001]
  • [Cites] Cancer. 1996 Oct 15;78(8):1829-37 [8859199.001]
  • [Cites] Am J Clin Pathol. 1997 Apr;107(4):494; author reply 494-5 [9124219.001]
  • [Cites] J Natl Cancer Inst. 2005 Feb 2;97(3):219-25 [15687365.001]
  • [Cites] J Clin Oncol. 2005 Dec 1;23(34):8671-8 [16314627.001]
  • [Cites] J Clin Oncol. 2006 Aug 1;24(22):3570-5 [16877723.001]
  • [Cites] Ann Surg. 2006 Oct;244(4):602-10 [16998369.001]
  • [Cites] J Natl Cancer Inst. 2007 Mar 21;99(6):414-5 [17374823.001]
  • [Cites] J Natl Cancer Inst. 2007 Mar 21;99(6):433-41 [17374833.001]
  • [Cites] JAMA. 2007 Nov 14;298(18):2149-54 [18000198.001]
  • [Cites] JAMA. 2007 Nov 14;298(18):2194-5 [18000205.001]
  • [Cites] Lancet. 2007 Dec 15;370(9604):2020-9 [18083404.001]
  • [Cites] JAMA. 2008 Feb 27;299(8):896-7; author reply 897-8 [18314429.001]
  • [Cites] J Natl Cancer Inst. 2008 Sep 17;100(18):1310-7 [18780863.001]
  • [Cites] Int J Colorectal Dis. 2009 Mar;24(3):283-8 [18716784.001]
  • [Cites] Am J Surg Pathol. 2002 Feb;26(2):179-89 [11812939.001]
  • (PMID = 19901106.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC3651597
  •  go-up   go-down


65. Luo R, Giordano SH, Zhang DD, Freeman J, Goodwin JS: The role of the surgeon in whether patients with lymph node-positive colon cancer see a medical oncologist. Cancer; 2007 Mar 1;109(5):975-82
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of the surgeon in whether patients with lymph node-positive colon cancer see a medical oncologist.
  • BACKGROUND: Chemotherapy improves survival for patients with stage III colon cancer, but some older patients with lymph node-positive colon cancer do not see a medical oncologist and, thus, do not receive adjuvant chemotherapy.
  • METHODS: To evaluate the role of the surgeon in determining referrals to medical oncology among patients with stage III colon cancer, the authors conducted a retrospective cohort study of 6158 patients aged >or=66 years who were diagnosed with stage III colon cancer from 1992 through 1999 by using the Surveillance, Epidemiology, and End Results-Medicare linked database.
  • The individual surgeon characteristics that significantly predicted whether the patient saw a medical oncologist were year since graduation (<or=10 years vs >20 years; hazard ratio [HR], 1.60; 95% confidence interval [95% CI], 1.19-2.16), practicing in a teaching hospital (yes vs. no: HR; 1.30; 95% CI, 1.07-1.58), and volume of patients with colon cancer (<30 patients vs >or=121 patients; HR, 0.66; 95% CI, 0.46-0.94).
  • Interventions at the level of the surgeon may be appropriate to improve the care of patients with colon cancer.

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Epidemiol. 2000 Dec;53(12):1258-67 [11146273.001]
  • [Cites] Oncologist. 2006 Oct;11(9):1025-33 [17030645.001]
  • [Cites] Cancer J. 2001 May-Jun;7(3):213-8 [11419029.001]
  • [Cites] N Engl J Med. 2001 Oct 11;345(15):1091-7 [11596588.001]
  • [Cites] Ann Intern Med. 2002 Mar 5;136(5):349-57 [11874307.001]
  • [Cites] J Clin Oncol. 2002 Apr 1;20(7):1716-8 [11919225.001]
  • [Cites] J Clin Oncol. 2002 Apr 1;20(7):1786-92 [11919235.001]
  • [Cites] Med Care. 2002 Aug;40(8 Suppl):IV-3-18 [12187163.001]
  • [Cites] Med Care. 2002 Aug;40(8 Suppl):IV-82-95 [12187173.001]
  • [Cites] Med Care. 2002 Aug;40(8 Suppl):IV-96-103 [12187174.001]
  • [Cites] Ann Surg Oncol. 2003 Jul;10(6):606-15 [12839844.001]
  • [Cites] J Clin Oncol. 2003 Dec 15;21(24):4627-35 [14673052.001]
  • [Cites] Med Care. 2004 Sep;42(9):901-6 [15319616.001]
  • [Cites] Med Care. 1985 Aug;23(8):939-45 [4021579.001]
  • [Cites] Med Care. 1991 Jan;29(1):50-63 [1986177.001]
  • [Cites] BMJ. 1991 May 25;302(6787):1250-2 [2043851.001]
  • [Cites] Cancer. 1993 Jul 15;72(2):594-601 [8319193.001]
  • [Cites] Gastroenterology. 1994 Apr;106(4):899-906 [8143995.001]
  • [Cites] Br J Cancer. 1994 Aug;70(2):363-70 [8054286.001]
  • [Cites] N Engl J Med. 1994 Dec 15;331(24):1625-9 [7969344.001]
  • [Cites] Lancet. 1995 Apr 15;345(8955):939-44 [7715291.001]
  • [Cites] Med Care. 1996 May;34(5):479-89 [8614169.001]
  • [Cites] Health Serv Res. 1996 Apr;31(1):5-19 [8617610.001]
  • [Cites] Cancer. 1996 Aug 15;78(4):918-26 [8756390.001]
  • [Cites] J Fam Pract. 1997 Jul;45(1):47-53 [9228914.001]
  • [Cites] J Clin Oncol. 1998 Jan;16(1):295-300 [9440756.001]
  • [Cites] J Clin Oncol. 1999 May;17(5):1349-55 [10334518.001]
  • [Cites] Lancet. 2005 Jan 8-14;365(9454):153-65 [15639298.001]
  • [Cites] J Natl Cancer Inst. 2005 Aug 17;97(16):1211-20 [16106026.001]
  • [Cites] JAMA. 2005 Dec 7;294(21):2703-11 [16333005.001]
  • [Cites] J Natl Cancer Inst. 2001 Jun 6;93(11):850-7 [11390534.001]
  • (PMID = 17265530.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA105631; United States / NCI NIH HHS / CA / R01 CA104949; United States / AHRQ HHS / HS / R24 HS011618
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS19823; NLM/ PMC1851914
  •  go-up   go-down


66. Arkenau HT, Rettig K, Porschen R: Adjuvant chemotherapy in curative resected colon carcinoma: 5-fluorouracil/leucovorin versus high-dose 5-fluorouracil 24-h infusion/leucovorin versus high-dose 5-fluorouracil 24-h infusion. Int J Colorectal Dis; 2005 May;20(3):258-61
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant chemotherapy in curative resected colon carcinoma: 5-fluorouracil/leucovorin versus high-dose 5-fluorouracil 24-h infusion/leucovorin versus high-dose 5-fluorouracil 24-h infusion.
  • BACKGROUND: Adjuvant postoperative treatment with 5-fluorouracil (5-FU) and leucovorin in curatively resected stage III colon cancer significantly reduces the risk of cancer recurrence and improves survival.
  • PATIENTS AND METHODS: Patients with a curatively resected UICC stage III colon cancer were stratified according to T, N and G category and randomly assigned to receive one of the three adjuvant treatment schemes: 5-FU 450 mg/m2 and leucovorin 100 mg/m2 x 5 days every 4 weeks; six cycles, arm A; 24-h infusion of high-dose 5-FU/leucovorin 2,600 mg/m2 and 500 mg/m2, two cycles of six applications, arm B; 24-h infusion of high-dose 5-FU 2,600 mg/m2, two cycles of six applications, arm C.
  • CONCLUSION: There is no statistical difference in efficacy and toxicity in patients receiving either high-dose 5-FU with or without leucovorin or the standard 5-FU bolus regime after a curative resection of a stage III colon cancer.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antimetabolites, Antineoplastic / administration & dosage. Colectomy / methods. Colonic Neoplasms / drug therapy. Fluorouracil / administration & dosage. Leucovorin / administration & dosage

  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15549327.001).
  • [ISSN] 0179-1958
  • [Journal-full-title] International journal of colorectal disease
  • [ISO-abbreviation] Int J Colorectal Dis
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


67. Billingsley KG, Morris AM, Dominitz JA, Matthews B, Dobie S, Barlow W, Wright GE, Baldwin LM: Surgeon and hospital characteristics as predictors of major adverse outcomes following colon cancer surgery: understanding the volume-outcome relationship. Arch Surg; 2007 Jan;142(1):23-31; discussion 32
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgeon and hospital characteristics as predictors of major adverse outcomes following colon cancer surgery: understanding the volume-outcome relationship.
  • PATIENTS: Patients aged 66 years and older, diagnosed and surgically treated for stage I, II, or III colon cancer between 1992 and 1996 (n = 22 672).
  • [MeSH-major] Adenocarcinoma / surgery. Colonic Neoplasms / surgery. Digestive System Surgical Procedures / utilization. Hospitals / utilization. Outcome Assessment (Health Care)

  • MedlinePlus Health Information. consumer health - Health Facilities.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17224497.001).
  • [ISSN] 0004-0010
  • [Journal-full-title] Archives of surgery (Chicago, Ill. : 1960)
  • [ISO-abbreviation] Arch Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


68. Sinicrope F, Foster NR, Sargent DJ, Thibodeau SN, Smyrk TC, O'Connell MJ, North Central Cancer Treatment Group: Model-based prediction of defective DNA mismatch repair using clinicopathological variables in sporadic colon cancer patients. Cancer; 2010 Apr 1;116(7):1691-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Model-based prediction of defective DNA mismatch repair using clinicopathological variables in sporadic colon cancer patients.
  • BACKGROUND: : Colon cancers with defective DNA mismatch repair (MMR) have a favorable prognosis and may lack benefit from 5-fluorouracil-based adjuvant chemotherapy.
  • The authors developed models to predict MMR deficiency in sporadic colon cancer patients using routine clinical and pathological data.
  • METHODS: : TNM stage II and III colon carcinomas (n = 982) from 6 5-fluorouracil-based adjuvant therapy trials were analyzed for microsatellite instability and/or MMR protein expression.
  • CONCLUSIONS: : Defective MMR is rare in distal, sporadic colon cancers, which should generally not undergo MMR testing.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2006 May 20;24(15):2359-67 [16710035.001]
  • [Cites] Gut. 2006 Jun;55(6):848-55 [16299036.001]
  • [Cites] Gastroenterology. 2006 Sep;131(3):729-37 [16952542.001]
  • [Cites] Int J Cancer. 2007 Mar 15;120(6):1232-8 [17187355.001]
  • [Cites] Gastroenterology. 2007 Jul;133(1):48-56 [17631130.001]
  • [Cites] J Clin Oncol. 2007 Aug 10;25(23):3534-42 [17687158.001]
  • [Cites] Am J Clin Pathol. 2008 Feb;129(2):238-44 [18208804.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Int J Cancer. 2008 Dec 1;123(11):2587-93 [18798261.001]
  • [Cites] Gastroenterology. 2008 Oct;135(4):1079-99 [18773902.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Nov;17(11):3208-15 [18990764.001]
  • [Cites] J Clin Oncol. 2008 Dec 10;26(35):5783-8 [18809606.001]
  • [Cites] Eur J Cancer. 2009 Feb;45(3):365-73 [18722765.001]
  • [Cites] Cancer. 2000 Apr 1;88(7):1739-57 [10738234.001]
  • [Cites] Cancer Res. 2000 Apr 15;60(8):2225-31 [10786688.001]
  • [Cites] Cancer. 2000 Nov 15;89(10):2025-37 [11066042.001]
  • [Cites] J Natl Cancer Inst. 2000 Nov 15;92(22):1831-6 [11078760.001]
  • [Cites] Am J Pathol. 2001 Feb;158(2):527-35 [11159189.001]
  • [Cites] Cancer. 2001 Jun 15;91(12):2417-22 [11413533.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2001 Sep;10(9):917-23 [11535541.001]
  • [Cites] Am J Pathol. 2001 Dec;159(6):2107-16 [11733361.001]
  • [Cites] Cancer Res. 2002 Jan 1;62(1):53-7 [11782358.001]
  • [Cites] J Clin Oncol. 2002 Feb 15;20(4):1043-8 [11844828.001]
  • [Cites] Cancer Res. 2002 Feb 15;62(4):1166-70 [11861399.001]
  • [Cites] J Clin Oncol. 2002 Apr 1;20(7):1711-3 [11919223.001]
  • [Cites] N Engl J Med. 2003 Jul 17;349(3):247-57 [12867608.001]
  • [Cites] Gastroenterology. 2004 Feb;126(2):394-401 [14762775.001]
  • [Cites] J Natl Cancer Inst. 2004 Feb 18;96(4):261-8 [14970275.001]
  • [Cites] Science. 1993 May 7;260(5109):816-9 [8484122.001]
  • [Cites] Am J Pathol. 1994 Jul;145(1):148-56 [8030745.001]
  • [Cites] Anticancer Res. 1994 Jul-Aug;14(4B):1657-60 [7979203.001]
  • [Cites] Cancer Res. 1998 Apr 15;58(8):1713-8 [9563488.001]
  • [Cites] Gut. 1998 May;42(5):673-9 [9659163.001]
  • [Cites] Cancer Res. 1998 Aug 1;58(15):3455-60 [9699680.001]
  • [Cites] Cancer Res. 1998 Nov 15;58(22):5248-57 [9823339.001]
  • [Cites] Am J Pathol. 1999 Jun;154(6):1805-13 [10362805.001]
  • [Cites] J Natl Cancer Inst. 1999 Aug 4;91(15):1295-303 [10433618.001]
  • [Cites] J Clin Oncol. 2005 Jan 20;23(3):609-18 [15659508.001]
  • [Cites] Clin Cancer Res. 2005 Dec 1;11(23):8332-40 [16322293.001]
  • [Cites] Clin Cancer Res. 2006 May 1;12(9):2738-44 [16675565.001]
  • [Cites] Am J Gastroenterol. 2006 May;101(5):1104-11 [16696788.001]
  • [Cites] Clin Colorectal Cancer. 2006 Jul;6(2):133-9 [16945169.001]
  • (PMID = 20186699.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA15083; United States / NCI NIH HHS / CA / CA104683-02; United States / NCI NIH HHS / CA / P30 CA015083; United States / NCI NIH HHS / CA / R01 CA104683; United States / NCI NIH HHS / CA / K05 CA142885; United States / NCI NIH HHS / CA / R01 CA104683-02; United States / NCI NIH HHS / CA / N01 CA015083
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS163421; NLM/ PMC2855300
  •  go-up   go-down


69. West NP, Morris EJ, Rotimi O, Cairns A, Finan PJ, Quirke P: Pathology grading of colon cancer surgical resection and its association with survival: a retrospective observational study. Lancet Oncol; 2008 Sep;9(9):857-65
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pathology grading of colon cancer surgical resection and its association with survival: a retrospective observational study.
  • We aimed to assess the quality of colon cancer surgery by studying the extent of variation in the plane of surgical resection, the amount of tissue removed, and its association with survival.
  • METHODS: All resections for primary colon adenocarcinoma done at Leeds General Infirmary (Leeds, UK) between Jan 1, 1997, and June 30, 2002, were identified.
  • However, this association was no longer significant in the multivariate model (HR 0.86 [95% CI 0.56-1.31], p=0.472), but was especially noted in patients with stage III cancers (HR 0.45 [95% CI 0.24-0.85], p=0.014; multivariate analysis).
  • INTERPRETATION: As previously shown in the rectum, we have now shown there is marked variability in the plane of surgery achieved in colon cancer.
  • Improving the plane of dissection might improve survival, especially in patients with stage III disease.
  • If confirmed by clinical trial data, such as from the ongoing National Cancer Research Institute Fluoropyrimidine, Oxaliplatin and Targeted Receptor pre-Operative Therapy for colon cancer (FOxTROT) trial of neoadjuvant chemotherapy in advanced resectable colon cancer, improvement of the plane of dissection might be a new cost-effective method of decreasing morbidity and mortality in patients with colon cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Lancet Oncol. 2008 Sep;9(9):815-7 [18760238.001]
  • (PMID = 18667357.001).
  • [ISSN] 1474-5488
  • [Journal-full-title] The Lancet. Oncology
  • [ISO-abbreviation] Lancet Oncol.
  • [Language] ENG
  • [Grant] United Kingdom / Cancer Research UK / / 9805; United Kingdom / Department of Health / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


70. Morris M, Platell C, Iacopetta B: Tumor-infiltrating lymphocytes and perforation in colon cancer predict positive response to 5-fluorouracil chemotherapy. Clin Cancer Res; 2008 Mar 1;14(5):1413-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor-infiltrating lymphocytes and perforation in colon cancer predict positive response to 5-fluorouracil chemotherapy.
  • The aim of the present study was to investigate the prognostic significance of TILs and other routinely reported pathologic features in colon cancer, particularly in relation to the use of adjuvant chemotherapy.
  • EXPERIMENTAL DESIGN: Pathologic markers, disease-specific survival, and the use of adjuvant chemotherapy were recorded in a retrospective, population-based series of 1,156 stage III colon cancer patients with a median follow-up time of 52 months.
  • RESULTS: In patients treated by surgery alone (n = 851), markers with significant prognostic value included poor histologic grade, T4 stage, N2 nodal status, vascular invasion, and perforation, but not the presence of TILs.
  • Because the presence of TILs reflects an adaptive immune response and perforation is associated with inflammatory response, these results suggest that there may be interactions between the immune system and chemotherapy leading to improved survival of colon cancer patients.
  • [MeSH-major] Adenocarcinoma, Mucinous / drug therapy. Antimetabolites, Antineoplastic / therapeutic use. Colonic Neoplasms / drug therapy. Fluorouracil / therapeutic use. Intestinal Perforation / diagnosis. Lymphocytes, Tumor-Infiltrating / pathology

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18316563.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; U3P01618RT / Fluorouracil
  •  go-up   go-down


71. Henry LR, Lee HO, Lee JS, Klein-Szanto A, Watts P, Ross EA, Chen WT, Cheng JD: Clinical implications of fibroblast activation protein in patients with colon cancer. Clin Cancer Res; 2007 Mar 15;13(6):1736-41
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical implications of fibroblast activation protein in patients with colon cancer.
  • PURPOSE: Human fibroblast activation protein (FAP)/seprase is a 97-kDa surface glycoprotein expressed on tumor associated fibroblasts in the majority of epithelial cancers including colon adenocarcinomas.
  • The primary objective of this study was to evaluate the clinical significance of stromal FAP in human colon cancers by immunohistochemisty.
  • EXPERIMENTAL DESIGN: Sections of paraffin-embedded resected primary human colon cancer specimens from 1996 through 2001 within the Fox Chase Cancer Center tumor bank were stained with D8 antibody directed against FAP/seprase.
  • RESULTS: One hundred thirty-eight patients with resected specimens were available for study (mean follow-up, 1,050 days) with 6 (4%) stage I, 52 (38%) stage II, 43 (31%) stage III, and 37 (27%) stage IV patients.
  • Stromal FAP was found to correlate inversely with tumor stage (semiquantitative, P = 0.01; intensity, P = 0.009) and with tumor size of the tumor xenograft model (correlation coefficient, -0.61; P = 0.047), suggesting that stromal FAP may have a greater role in the early development of tumors.
  • CONCLUSION: Our data indicate that patients whose colon tumors have high levels of stromal FAP are more likely to have aggressive disease progression and potential development of metastases or recurrence.
  • It also suggests that the effects of FAP inhibition should be investigated in earlier-stage tumors, given its high levels and potential effect earlier in the course of the disease.
  • [MeSH-major] Adenocarcinoma / genetics. Antigens, Neoplasm / genetics. Biomarkers, Tumor / genetics. Colonic Neoplasms / genetics. Gene Expression Regulation, Neoplastic. Serine Endopeptidases / genetics

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17363526.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA006927; United States / NCI NIH HHS / CA / CA09035; United States / NCI NIH HHS / CA / CA090468; United States / NCI NIH HHS / CA / CA103991; United States / PHS HHS / / W81XWH-04-1-0709
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Membrane Proteins; EC 3.4.21.- / Serine Endopeptidases; EC 3.4.21.- / fibroblast activation protein alpha; EC 3.4.24.- / Gelatinases
  •  go-up   go-down


72. Smith JJ, Deane NG, Wu F, Merchant NB, Zhang B, Jiang A, Lu P, Johnson JC, Schmidt C, Bailey CE, Eschrich S, Kis C, Levy S, Washington MK, Heslin MJ, Coffey RJ, Yeatman TJ, Shyr Y, Beauchamp RD: Experimentally derived metastasis gene expression profile predicts recurrence and death in patients with colon cancer. Gastroenterology; 2010 Mar;138(3):958-68
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Experimentally derived metastasis gene expression profile predicts recurrence and death in patients with colon cancer.
  • BACKGROUND & AIMS: Staging inadequately predicts metastatic risk in patients with colon cancer.
  • We used a gene expression profile derived from invasive, murine colon cancer cells that were highly metastatic in an immunocompetent mouse model to identify patients with colon cancer at risk of recurrence.
  • The metastasis-associated gene expression profile developed from the mouse model was refined with comparative functional genomics in the VMC gene expression profiles to identify a 34-gene classifier associated with high risk of metastasis and death from colon cancer.
  • RESULTS: A high score was significantly associated with increased risk of metastasis and death from colon cancer across all pathologic stages and specifically in stage II and stage III patients.
  • For example, among stage III patients, a high score translated to increased relative risk of cancer recurrence (hazard ratio, 4.7; 95% confidence interval, 1.566-14.05).
  • Furthermore, the metastasis score identified patients with stage III disease whose 5-year recurrence-free survival was >88% and for whom adjuvant chemotherapy did not increase survival time.
  • CONCLUSION: A gene expression profile identified from an experimental model of colon cancer metastasis predicted cancer recurrence and death, independently of conventional measures, in patients with colon cancer.

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Genetic Testing.
  • COS Scholar Universe. author profiles.
  • SciCrunch. ArrayExpress: Data: Microarray .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 AGA Institute. Published by Elsevier Inc. All rights reserved.
  • [Cites] Acta Oncol. 2001;40(2-3):282-308 [11441937.001]
  • [Cites] N Engl J Med. 2001 Feb 22;344(8):539-48 [11207349.001]
  • [Cites] Nat Med. 2002 Aug;8(8):816-24 [12118244.001]
  • [Cites] Lancet. 2003 Aug 9;362(9382):433-9 [12927430.001]
  • [Cites] Clin Exp Metastasis. 2003;20(8):733-44 [14713107.001]
  • [Cites] PLoS Biol. 2004 Feb;2(2):E7 [14737219.001]
  • [Cites] J Clin Oncol. 2004 May 1;22(9):1564-71 [15051756.001]
  • [Cites] Carcinogenesis. 2000 Apr;21(4):757-68 [10753213.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Dec 9;105(49):19432-7 [19050079.001]
  • [Cites] Cancer Res. 2001 Mar 15;61(6):2395-8 [11289103.001]
  • [Cites] J Clin Oncol. 2004 May 15;22(10):1797-806 [15067028.001]
  • [Cites] J Clin Oncol. 2004 Aug 15;22(16):3395-407 [15199087.001]
  • [Cites] J Clin Oncol. 2004 Aug 15;22(16):3408-19 [15199089.001]
  • [Cites] Gastroenterology. 2004 Nov;127(5 Suppl 1):S51-5 [15508103.001]
  • [Cites] Clin Oncol. 1976 Jun;2(2):131-40 [182425.001]
  • [Cites] J Natl Cancer Inst. 1976 Nov;57(5):1199-202 [1003551.001]
  • [Cites] Proc Natl Acad Sci U S A. 1981 Oct;78(10):6226-30 [6947225.001]
  • [Cites] JAMA. 1982 May 14;247(18):2543-6 [7069920.001]
  • [Cites] J Natl Cancer Inst. 1986 Feb;76(2):309-22 [3484792.001]
  • [Cites] Control Clin Trials. 1993 Aug;14(4):266-85 [8365193.001]
  • [Cites] J Clin Oncol. 1999 May;17(5):1349-55 [10334518.001]
  • [Cites] Nat Genet. 2004 Dec;36(12):1306-11 [15565109.001]
  • [Cites] N Engl J Med. 2004 Dec 30;351(27):2817-26 [15591335.001]
  • [Cites] Bioinformatics. 2005 May 1;21(9):2067-75 [15657102.001]
  • [Cites] J Clin Oncol. 2005 May 20;23(15):3526-35 [15908663.001]
  • [Cites] J Clin Invest. 2006 Jun;116(6):1582-95 [16710476.001]
  • [Cites] J Clin Oncol. 2006 Oct 10;24(29):4685-91 [16966692.001]
  • [Cites] Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):498-507 [17255271.001]
  • [Cites] Lancet. 2007 Dec 15;370(9604):2020-9 [18083404.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Cochrane Database Syst Rev. 2008;(3):CD005390 [18646127.001]
  • [Cites] Cancer Lett. 2008 Aug 28;267(2):197-203 [18406516.001]
  • [Cites] Nat Med. 2008 Aug;14(8):822-7 [18641660.001]
  • [Cites] N Engl J Med. 2008 Nov 6;359(19):1995-2004 [18923165.001]
  • [Cites] Mol Ther. 2001 Oct;4(4):297-306 [11592831.001]
  • (PMID = 19914252.001).
  • [ISSN] 1528-0012
  • [Journal-full-title] Gastroenterology
  • [ISO-abbreviation] Gastroenterology
  • [Language] ENG
  • [Databank-accession-numbers] GEO/ GSE17538
  • [Grant] United States / NCI NIH HHS / CA / CA46413; United States / NCI NIH HHS / CA / CA077839; United States / NCI NIH HHS / CA / P50 CA128323; United States / NIDDK NIH HHS / DK / DK52334; United States / NCI NIH HHS / CA / P50 CA095103; United States / NCI NIH HHS / CA / R01 CA046413; United States / NCI NIH HHS / CA / T32 CA106183; United States / NCI NIH HHS / CA / CA112215; United States / NCI NIH HHS / CA / R01 CA112215; United States / NCI NIH HHS / CA / CA126588; United States / NCRR NIH HHS / RR / TL1 RR024978; United States / NCI NIH HHS / CA / U24 CA126588; United States / NCI NIH HHS / CA / P01 CA077839; United States / NCI NIH HHS / CA / CA106183; United States / NCI NIH HHS / CA / CA084239; United States / NCI NIH HHS / CA / U01 CA084239; United States / NCI NIH HHS / CA / P30 CA068485; United States / NCI NIH HHS / CA / R01 CA069457; United States / NCI NIH HHS / CA / CA95103; United States / NIDDK NIH HHS / DK / R01 DK052334; United States / NCI NIH HHS / CA / CA128323; United States / NCI NIH HHS / CA / CA068485; United States / NCI NIH HHS / CA / CA69457
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS388171; NLM/ PMC3388775
  •  go-up   go-down


73. Chung KY, Kelsen D: Adjuvant Therapy for Stage II Colorectal Cancer: Who and with What? Curr Treat Options Gastroenterol; 2006 Jun;9(3):272-80

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant Therapy for Stage II Colorectal Cancer: Who and with What?
  • The role of adjuvant chemotherapy for patients with stage II colon adenocarcinoma remains controversial.
  • The high surgical cure rate for patients with "low-risk" stage II colon cancer, ranging from 75% to 80%, and the available clinical trials and meta-analyses provide conflicting recommendations for or against adjuvant chemotherapy for this group of patients.
  • For fit "high-risk" stage II patients with clinical obstruction or perforation at presentation, in which the 5-year survival rate is 60% to 70%, there is little controversy, as these patients are routinely treated with adjuvant chemotherapy.
  • These patients may have stage III disease and should receive adjuvant therapy.
  • The decision to use adjuvant chemotherapy to treat low-risk stage II colon cancer patients (no obstruction or perforation) should be an informed decision weighing the magnitude of a net 2% to 5% survival benefit, a 0.5% to 1.0% risk of mortality with chemotherapy in addition to 6 months of chemotherapy-related toxicities, other coexisting patient morbidities, and the anticipated life expectancy of each patient.
  • As adjuvant chemotherapy is therapy addressing local or metastatic microscopic disease, and the effectiveness of systemic and biologically targeted therapy for advanced macroscopic colon cancer continues to improve rapidly, it remains to be determined by clinical trials whether therapies including newer agents such as cetuximab and bevacizumab administered in the adjuvant setting may affect survival for stage II cancer patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16901391.001).
  • [ISSN] 1092-8472
  • [Journal-full-title] Current treatment options in gastroenterology
  • [ISO-abbreviation] Curr Treat Options Gastroenterol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


74. Sinicrope FA, Rego RL, Ansell SM, Knutson KL, Foster NR, Sargent DJ: Intraepithelial effector (CD3+)/regulatory (FoxP3+) T-cell ratio predicts a clinical outcome of human colon carcinoma. Gastroenterology; 2009 Oct;137(4):1270-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraepithelial effector (CD3+)/regulatory (FoxP3+) T-cell ratio predicts a clinical outcome of human colon carcinoma.
  • We investigated whether the intratumoral densities of FoxP3(+) and effector CD3(+) lymphocytes are associated with prognosis of patients with colon cancer.
  • METHODS: FoxP3 and CD3 expression and location were determined in stage II and III colon carcinomas (n = 160) and normal mucosa (n = 25) by immunohistochemistry; CD4 and FoxP3 were localized by dual immunofluorescence microscopy.
  • By multivariate analysis, a low CD3(+)/FoxP3(+) cell ratio (P= .0318) and low numbers of CD3(+) T cells (P = .0397) predicted shorter DFS times and were stronger prognostic variables than tumor stage or number of lymph node metastases.
  • CONCLUSIONS: A low intraepithelial CD3(+)/FoxP3(+) cell ratio and reduced numbers of CD3(+) T cells were associated with shorter patient survival time, indicating the importance of an effector to Treg cell ratio in colon cancer prognosis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 1998 Aug 15;58(16):3491-4 [9721846.001]
  • [Cites] Cancer Immunol Immunother. 2009 Jan;58(1):135-44 [18488217.001]
  • [Cites] J Natl Cancer Inst. 1999 Aug 4;91(15):1295-303 [10433618.001]
  • [Cites] J Clin Oncol. 2005 Jan 20;23(3):609-18 [15659508.001]
  • [Cites] J Exp Med. 2005 Mar 7;201(5):779-91 [15753211.001]
  • [Cites] Nat Immunol. 2005 Apr;6(4):331-7 [15785758.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jun 28;102(26):9253-7 [15961541.001]
  • [Cites] Clin Cancer Res. 2005 Dec 1;11(23):8326-31 [16322292.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Dec 20;102(51):18538-43 [16344461.001]
  • [Cites] Clin Cancer Res. 2006 Feb 15;12(4):1144-51 [16489067.001]
  • [Cites] CA Cancer J Clin. 2006 Mar-Apr;56(2):106-30 [16514137.001]
  • [Cites] Annu Rev Immunol. 2006;24:209-26 [16551248.001]
  • [Cites] Nat Rev Immunol. 2006 Apr;6(4):295-307 [16557261.001]
  • [Cites] Nat Genet. 2006 Jul;38(7):787-93 [16804544.001]
  • [Cites] J Clin Invest. 2006 Jul;116(7):1935-45 [16778987.001]
  • [Cites] Clin Colorectal Cancer. 2006 Jul;6(2):133-9 [16945169.001]
  • [Cites] Gastroenterology. 2006 Sep;131(3):729-37 [16952542.001]
  • [Cites] Science. 2006 Sep 29;313(5795):1960-4 [17008531.001]
  • [Cites] Cancer Res. 2006 Oct 15;66(20):10145-52 [17047079.001]
  • [Cites] J Clin Oncol. 2006 Dec 1;24(34):5373-80 [17135638.001]
  • [Cites] Cancer. 2006 Dec 15;107(12):2866-72 [17099880.001]
  • [Cites] PLoS One. 2006;1:e129 [17205133.001]
  • [Cites] Eur J Cancer. 2007 Feb;43(3):624-31 [17223543.001]
  • [Cites] Int J Cancer. 2007 Mar 15;120(6):1232-8 [17187355.001]
  • [Cites] Cancer Immun. 2007;7:7 [17388261.001]
  • [Cites] Clin Cancer Res. 2007 Apr 1;13(7):2075-81 [17404089.001]
  • [Cites] J Immunol. 1999 Nov 15;163(10):5211-8 [10553041.001]
  • [Cites] Nat Genet. 2001 Jan;27(1):68-73 [11138001.001]
  • [Cites] Gut. 2001 Mar;48(3):360-6 [11171826.001]
  • [Cites] Am J Pathol. 2001 Jul;159(1):297-304 [11438476.001]
  • [Cites] Clin Exp Immunol. 2002 Jan;127(1):85-91 [11882037.001]
  • [Cites] J Clin Oncol. 2002 Apr 1;20(7):1735-43 [11919229.001]
  • [Cites] J Immunol. 2002 Sep 1;169(5):2756-61 [12193750.001]
  • [Cites] N Engl J Med. 2003 Jan 16;348(3):203-13 [12529460.001]
  • [Cites] Clin Cancer Res. 2003 Feb;9(2):606-12 [12576425.001]
  • [Cites] Science. 2003 Feb 14;299(5609):1057-61 [12522256.001]
  • [Cites] Nat Rev Immunol. 2003 Mar;3(3):253-7 [12658273.001]
  • [Cites] Nat Immunol. 2003 Apr;4(4):330-6 [12612578.001]
  • [Cites] Eur J Cancer. 2003 Mar;39(4):469-75 [12751377.001]
  • [Cites] Cancer. 2003 Sep 1;98(5):1089-99 [12942579.001]
  • [Cites] Jpn J Clin Oncol. 2004 Feb;34(2):90-8 [15067103.001]
  • [Cites] J Immunol. 2004 May 1;172(9):5287-96 [15100267.001]
  • [Cites] J Immunol. 2004 Jul 15;173(2):1444-53 [15240741.001]
  • [Cites] Nat Med. 2004 Sep;10(9):942-9 [15322536.001]
  • [Cites] J Exp Med. 2004 Sep 20;200(6):771-82 [15381730.001]
  • [Cites] J Natl Cancer Inst. 2004 Oct 6;96(19):1420-5 [15467030.001]
  • [Cites] Int Immunol. 2004 Nov;16(11):1643-56 [15466453.001]
  • [Cites] Br J Cancer. 2004 Nov 1;91(9):1711-7 [15494715.001]
  • [Cites] Eur J Cancer Clin Oncol. 1984 Dec;20(12):1485-7 [6238826.001]
  • [Cites] Cell Immunol. 1993 Jan;146(1):107-16 [7678783.001]
  • [Cites] Nature. 1993 Jun 10;363(6429):558-61 [8505985.001]
  • [Cites] Cancer Res. 1998 Apr 15;58(8):1713-8 [9563488.001]
  • [Cites] N Engl J Med. 1998 May 21;338(21):1481-7 [9593786.001]
  • [Cites] Gut. 1998 May;42(5):673-9 [9659163.001]
  • [Cites] Gastroenterology. 2007 Jun;132(7):2328-39 [17570208.001]
  • [Cites] J Clin Oncol. 2007 Jun 20;25(18):2586-93 [17577038.001]
  • [Cites] Semin Cancer Biol. 2007 Aug;17(4):275-87 [17662614.001]
  • [Cites] Immunity. 2007 Oct;27(4):635-46 [17919943.001]
  • [Cites] Gynecol Oncol. 2008 Feb;108(2):415-20 [18037158.001]
  • [Cites] Br J Cancer. 2008 Apr 8;98(7):1258-63 [18349839.001]
  • [Cites] Gastroenterology. 2008 Apr;134(4):988-97 [18395080.001]
  • [Cites] Eur J Hum Genet. 1999 May-Jun;7(4):407-8 [10352929.001]
  • (PMID = 19577568.001).
  • [ISSN] 1528-0012
  • [Journal-full-title] Gastroenterology
  • [ISO-abbreviation] Gastroenterology
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA15083; United States / NCI NIH HHS / CA / R01 CA104683-04; United States / NCI NIH HHS / CA / P30 CA015083; United States / NCI NIH HHS / CA / CA104683-02; United States / NCI NIH HHS / CA / R01 CA104683; United States / NCI NIH HHS / CA / CA104683-04; United States / NCI NIH HHS / CA / N01 CA015083
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD3; 0 / FOXP3 protein, human; 0 / Forkhead Transcription Factors
  • [Other-IDs] NLM/ NIHMS130072; NLM/ PMC2873775
  •  go-up   go-down


75. van Leeuwen BL, Påhlman L, Gunnarsson U, Sjövall A, Martling A: The effect of age and gender on outcome after treatment for colon carcinoma. A population-based study in the Uppsala and Stockholm region. Crit Rev Oncol Hematol; 2008 Sep;67(3):229-36

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The effect of age and gender on outcome after treatment for colon carcinoma. A population-based study in the Uppsala and Stockholm region.
  • RATIONALE: The aim of this study was to assess whether there are differences in treatment strategy and outcome between different age cohorts among men and women with colon cancer.
  • METHODS: All patients with colon cancer included in the regional quality registry in Uppsala/Orebro and Stockholm between 1996 and December 2004 were analysed (n=11002).
  • RESULTS: Overall and cancer-specific survival decreased with increasing age for stages II and III colon cancer but was not influenced by gender.
  • Older patients with stage III tumours were less likely to be referred for chemotherapeutic treatment and there was a decrease in cancer-specific survival with increasing age, from 63.7% to 51.0% to 38.4% in the three age groups.
  • [MeSH-minor] Adenocarcinoma. Age Distribution. Age Factors. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Cohort Studies. Combined Modality Therapy. Female. Humans. Male. Neoplasm Staging. Radiotherapy, Adjuvant. Registries. Sex Factors. Survival Analysis. Sweden. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18440820.001).
  • [ISSN] 1040-8428
  • [Journal-full-title] Critical reviews in oncology/hematology
  • [ISO-abbreviation] Crit. Rev. Oncol. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  •  go-up   go-down


76. Goswami RS, Minoo P, Baker K, Chong G, Foulkes WD, Jass JR: Hyperplastic polyposis and cancer of the colon with gastrinoma of the duodenum. Nat Clin Pract Oncol; 2006 May;3(5):281-4; quiz 285
MedlinePlus Health Information. consumer health - Intestinal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hyperplastic polyposis and cancer of the colon with gastrinoma of the duodenum.
  • DIAGNOSIS: Duodenal neuroendocrine neoplasm showing gastrin expression and stage III (T3N2M0), poorly differentiated adenocarcinoma of the cecum arising from hyperplastic polyposis.
  • [MeSH-major] Adenocarcinoma. Colonic Neoplasms. Colonic Polyps. Duodenal Neoplasms. Gastrinoma. Neoplasms, Multiple Primary

  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16683006.001).
  • [ISSN] 1743-4254
  • [Journal-full-title] Nature clinical practice. Oncology
  • [ISO-abbreviation] Nat Clin Pract Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


77. Huerta S, Heinzerling JH, Anguiano-Hernandez YM, Huerta-Yepez S, Lin J, Chen D, Bonavida B, Livingston EH: Modification of gene products involved in resistance to apoptosis in metastatic colon cancer cells: roles of Fas, Apaf-1, NFkappaB, IAPs, Smac/DIABLO, and AIF. J Surg Res; 2007 Sep;142(1):184-94
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Modification of gene products involved in resistance to apoptosis in metastatic colon cancer cells: roles of Fas, Apaf-1, NFkappaB, IAPs, Smac/DIABLO, and AIF.
  • BACKGROUND: Colon cancer becomes resistant to apoptosis as it acquires metastatic potential.
  • SW480 and SW620 colon cancer cells were established from the same patient at different stages of tumor progression.
  • The stage III colorectal cancer cell line (SW620) is more resistant to apoptosis.
  • In the present report, we investigated the apoptotic gene products that might account for colon cancer evasion of immune attack and chemoradioresistance-induced apoptosis.
  • CONCLUSIONS: SW620 cells have acquired genetic defects both in the intrinsic and extrinsic pathways of apoptosis, which may explain in part the ability of colon cancer cells to escape the immune system and to become chemoradioresistant.
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / physiopathology. Antibodies / pharmacology. Antineoplastic Agents / pharmacology. Apoptosomes / physiology. Cell Line, Tumor. Cisplatin / pharmacology. Colon / drug effects. Colon / pathology. Colon / radiation effects. Colonic Neoplasms / pathology. Colonic Neoplasms / physiopathology. Disease Progression. Gene Expression Regulation, Neoplastic. Humans. Neoplasm Metastasis / physiopathology. Proto-Oncogene Proteins c-bcl-2 / physiology. Receptors, Death Domain / physiology. Tumor Suppressor Protein p53 / physiology

  • Genetic Alliance. consumer health - Metastatic cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17603079.001).
  • [ISSN] 0022-4804
  • [Journal-full-title] The Journal of surgical research
  • [ISO-abbreviation] J. Surg. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / APAF1 protein, human; 0 / Antibodies; 0 / Antigens, CD95; 0 / Antineoplastic Agents; 0 / Apoptosis Inducing Factor; 0 / Apoptosomes; 0 / Apoptotic Protease-Activating Factor 1; 0 / CH-11 anti-fas antibody, human; 0 / DIABLO protein, human; 0 / Inhibitor of Apoptosis Proteins; 0 / Intracellular Signaling Peptides and Proteins; 0 / Mitochondrial Proteins; 0 / NF-kappa B; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Receptors, Death Domain; 0 / Tumor Suppressor Protein p53; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


78. Benevolo M, Mottolese M, Piperno G, Sperduti I, Cione A, Sibilio L, Martayan A, Donnorso RP, Cosimelli M, Giacomini P: HLA-A, -B, -C expression in colon carcinoma mimics that of the normal colonic mucosa and is prognostically relevant. Am J Surg Pathol; 2007 Jan;31(1):76-84
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HLA-A, -B, -C expression in colon carcinoma mimics that of the normal colonic mucosa and is prognostically relevant.
  • Herein, monoclonal antibodies with preferential reactivity for HLA-A, HLA-B, and HLA-C (HCA2, HC10, and L31) were used to stain an archival collection of 291 formalin-fixed/paraffin-embedded tissues, comprising neoplastic lesions from stages II and III colon carcinoma patients (n=165), and the uninvolved, morphologically normal mucosae from a subset (n=126) of these patients.
  • Deviations from the expression in the normal paired mucosa (both increases and decreases) of HCA2-reactive class I molecules (possibly HLA-A), and down-regulation of L31-reactive class I molecules (possibly HLA-C), particularly in tumors from stage II patients, correlated with poor 5-year overall and disease-free survival, hazard risk ranging from 2 to 6, approximately.
  • Thus, a paired immunohistochemical comparison reveals a novel immune evasion strategy that may impact on the prognosis of colon carcinoma.
  • [MeSH-major] Adenocarcinoma / metabolism. Colon / metabolism. Colorectal Neoplasms / metabolism. Histocompatibility Antigens Class I / metabolism. Intestinal Mucosa / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17197922.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Histocompatibility Antigens Class I
  •  go-up   go-down


79. Givalos N, Gakiopoulou H, Skliri M, Bousboukea K, Konstantinidou AE, Korkolopoulou P, Lelouda M, Kouraklis G, Patsouris E, Karatzas G: Replication protein A is an independent prognostic indicator with potential therapeutic implications in colon cancer. Mod Pathol; 2007 Feb;20(2):159-66
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Replication protein A is an independent prognostic indicator with potential therapeutic implications in colon cancer.
  • Experimental studies in colon cancer cell lines have shown that RPA protein may be the target of cytotoxins designed to inhibit cellular proliferation.
  • This is the first study to investigate the expression of RPA1 and RPA2 subunits of RPA protein and assess their prognostic value in colon cancer patients.
  • We analyzed immunohistochemically the expression of RPA1 and RPA2 proteins in a series of 130 colon cancer resection specimens in relation to conventional clinicopathological parameters and patients' survival.
  • Statistical significant positive associations emerged between: (a) RPA1 and RPA2 protein expressions (P=0.0001), (b) RPA1 and RPA2 labelling indices (LIs) and advanced stage of the disease (P=0.001 and 0.003, respectively), (c) RPA1 and RPA2 LIs and the presence of lymph node metastasis (P=0.002 and 0.004, respectively), (d) RPA1 LI and the number of infiltrated lymph nodes (P=0.021), (e) RPA2 LI and histological grade of carcinomas (P=0.05).
  • Statistical significant differences according to the expression of RPA1 and RPA2 proteins were also noticed in the survival of stage II (P<0.00001 and 0.0016, respectively) and stage III (P=0.0029 and 0.0079, respectively) patients.
  • In conclusion, RPA1 and RPA2 proteins appear to be useful prognostic indicators in colon cancer patients and attractive therapeutic targets for regulation by tumor suppressors or other proteins involved in the control of cell proliferation.
  • [MeSH-major] Adenocarcinoma / metabolism. Colon / metabolism. Colonic Neoplasms / metabolism. Replication Protein A / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17361204.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RPA1 protein, human; 0 / Replication Protein A; EC 2.7.7.7 / RPA2 protein, human
  •  go-up   go-down


80. Sträter J, Hinz U, Hasel C, Bhanot U, Mechtersheimer G, Lehnert T, Möller P: Impaired CD95 expression predisposes for recurrence in curatively resected colon carcinoma: clinical evidence for immunoselection and CD95L mediated control of minimal residual disease. Gut; 2005 May;54(5):661-5
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impaired CD95 expression predisposes for recurrence in curatively resected colon carcinoma: clinical evidence for immunoselection and CD95L mediated control of minimal residual disease.
  • BACKGROUND: Loss of CD95 expression in tumour cells occurs frequently in colon carcinoma and may be associated with disease progression.
  • AIMS: We aimed at further exploring the functional role and prognostic significance of the CD95/CD95L death inducing system in colon carcinomas.
  • PATIENTS AND METHODS: CD95 and CD95L expression was examined by immunohistochemistry in 128 R0 resected UICC (International Union against Cancer) stage II/III colon carcinomas and correlated with disease free survival.
  • Tumour infiltrating lymphocytes (TIL) were the major source of CD95L in colon carcinomas.
  • Moreover, a high rate of CD95L+TIL correlated with prolonged disease free survival in patients with UICC stage II (p = 0.05) but not in those with stage III.
  • CONCLUSIONS: Loss of CD95 in tumour cells may be an independent prognostic factor in colon carcinomas.
  • The CD95L counterattack is not a relevant feature in colon carcinoma but CD95L+TIL may contribute to tumour control in the early stages of the disease, exerting a concurrent selection pressure in the direction of CD95 abrogation/resistance.
  • [MeSH-major] Adenocarcinoma / immunology. Antigens, CD95 / metabolism. Biomarkers, Tumor / metabolism. Colonic Neoplasms / immunology. Membrane Glycoproteins / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Pathol. 1999 Nov;30(11):1309-13 [10571510.001]
  • [Cites] Cell Death Differ. 2001 Mar;8(3):273-8 [11319610.001]
  • [Cites] J Immunol. 2000 May 15;164(10):5023-7 [10799856.001]
  • [Cites] J Pathol. 2001 May;194(1):15-9 [11329136.001]
  • [Cites] J Immunol. 2001 Aug 15;167(4):2068-73 [11489989.001]
  • [Cites] Cancer Cell. 2002 Aug;2(2):139-48 [12204534.001]
  • [Cites] J Immunol. 2003 Jun 15;170(12):5973-80 [12794124.001]
  • [Cites] Gastroenterology. 2003 Sep;125(3):708-15 [12949717.001]
  • [Cites] J Immunol. 2003 Oct 15;171(8):4164-74 [14530339.001]
  • [Cites] Cancer. 1981 Mar 1;47(5):930-6 [7226044.001]
  • [Cites] Cell. 1991 Jul 26;66(2):233-43 [1713127.001]
  • [Cites] J Biol Chem. 1992 May 25;267(15):10709-15 [1375228.001]
  • [Cites] Lab Invest. 1993 Oct;69(4):415-29 [7693996.001]
  • [Cites] Int J Cancer. 1994 May 1;57(3):371-7 [8168998.001]
  • [Cites] Int J Cancer. 1996 Sep 4;67(5):709-14 [8782663.001]
  • [Cites] Science. 1996 Nov 22;274(5291):1363-6 [8910274.001]
  • [Cites] J Exp Med. 1996 Sep 1;184(3):1075-82 [9064324.001]
  • [Cites] J Exp Med. 1996 Sep 1;184(3):1149-54 [9064331.001]
  • [Cites] Cell. 1997 Feb 7;88(3):355-65 [9039262.001]
  • [Cites] Gastroenterology. 1997 Jul;113(1):160-7 [9207274.001]
  • [Cites] Cancer Res. 1998 Feb 1;58(3):526-34 [9458101.001]
  • [Cites] Cancer Res. 1998 Aug 15;58(16):3491-4 [9721846.001]
  • [Cites] J Exp Med. 1998 Nov 2;188(9):1717-23 [9802983.001]
  • [Cites] J Pathol. 1998 Nov;186(3):240-6 [10211111.001]
  • [Cites] J Exp Med. 1999 Oct 4;190(7):1025-32 [10510092.001]
  • [Cites] J Exp Med. 1999 Oct 4;190(7):1033-8 [10510093.001]
  • [Cites] J Immunol. 2000 May 1;164(9):4941-54 [10779805.001]
  • (PMID = 15831912.001).
  • [ISSN] 0017-5749
  • [Journal-full-title] Gut
  • [ISO-abbreviation] Gut
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD95; 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / FASLG protein, human; 0 / Fas Ligand Protein; 0 / Ligands; 0 / Membrane Glycoproteins
  • [Other-IDs] NLM/ PMC1774512
  •  go-up   go-down


81. Grade M, Hörmann P, Becker S, Hummon AB, Wangsa D, Varma S, Simon R, Liersch T, Becker H, Difilippantonio MJ, Ghadimi BM, Ried T: Gene expression profiling reveals a massive, aneuploidy-dependent transcriptional deregulation and distinct differences between lymph node-negative and lymph node-positive colon carcinomas. Cancer Res; 2007 Jan 1;67(1):41-56
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene expression profiling reveals a massive, aneuploidy-dependent transcriptional deregulation and distinct differences between lymph node-negative and lymph node-positive colon carcinomas.
  • To characterize patterns of global transcriptional deregulation in primary colon carcinomas, we did gene expression profiling of 73 tumors [Unio Internationale Contra Cancrum stage II (n = 33) and stage III (n = 40)] using oligonucleotide microarrays.
  • Seventeen genes had a >5-fold average expression difference between normal colon mucosa and carcinomas, including up-regulation of MYC and of HMGA1, a putative oncogene.
  • Finally, we established a relationship between specific genomic imbalances, which were mapped for 32 of the analyzed colon tumors by comparative genomic hybridization, and alterations of global transcriptional activity.
  • The systematic comparison of colon and rectal carcinomas revealed a significant overlap of genomic imbalances and transcriptional deregulation, including activation of the Wnt/beta-catenin signaling cascade, suggesting similar pathogenic pathways.
  • [MeSH-major] Adenocarcinoma / genetics. Adenocarcinoma / pathology. Aneuploidy. Colonic Neoplasms / genetics. Colonic Neoplasms / pathology. Lymph Nodes / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Colon / metabolism. Colon / physiology. Female. Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Genome, Human. Humans. Intestinal Mucosa / metabolism. Intestinal Mucosa / physiology. Lymphatic Metastasis. Male. Middle Aged. Multigene Family. Neoplasm Staging. Reverse Transcriptase Polymerase Chain Reaction

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17210682.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / Z99 CA999999
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS663105; NLM/ PMC4721580
  •  go-up   go-down


82. Gibson TB, Ranganathan A, Grothey A: Randomized phase III trial results of panitumumab, a fully human anti-epidermal growth factor receptor monoclonal antibody, in metastatic colorectal cancer. Clin Colorectal Cancer; 2006 May;6(1):29-31
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Randomized phase III trial results of panitumumab, a fully human anti-epidermal growth factor receptor monoclonal antibody, in metastatic colorectal cancer.
  • The results of a phase III trial which compared panitumumab as a single agent to best supportive care in patients with previously treated metastatic CRC have recently been reported Pantitumumab therapy resulted in a 46% reduction in the risk of tumor progression and a partial response rate of 8%.
  • Further clinical studies re ongoing and planned to test panitumumab in combination with chemotherapy in first-line therapy of advanced-stage CRC and adjuvant treatment of colon cancer.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / secondary. Antibodies, Monoclonal / therapeutic use. Colorectal Neoplasms / pathology


83. Kang H, O'Connell JB, Maggard MA, Sack J, Ko CY: A 10-year outcomes evaluation of mucinous and signet-ring cell carcinoma of the colon and rectum. Dis Colon Rectum; 2005 Jun;48(6):1161-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A 10-year outcomes evaluation of mucinous and signet-ring cell carcinoma of the colon and rectum.
  • This study used a national cancer registry to analyze the epidemiology and survival outcomes of these two subtypes of colorectal cancer compared with adenocarcinoma tumors.
  • METHODS: All patients diagnosed with mucinous (n = 16,991), signet-ring cell (n = 1,522), or adenocarcinoma (n = 146,115) colorectal cancer in the Surveillance, Epidemiology, and End Results database (1991-2000) were evaluated.
  • Analyses were performed to obtain age-adjusted incidence rates, stage at presentation, tumor grade, and five-year relative survival for each subtype.
  • Incidence rates per 100,000 persons were: mucinous, 5.5; signet-ring cell, 0.6; and adenocarcinoma 46.6.
  • The annual percent change during ten years was stable for mucinous, increased for signet-ring cell (4.8 percent; P < 0.05), and decreased for adenocarcinoma (-1.1 percent; P < 0.05).
  • Fewer mucinous (18 percent) and signet-ring cell (21 percent) tumors were located in the rectum compared with adenocarcinoma (29 percent).
  • Signet-ring cell presented at later stage (III/IV, 80.9 percent) more often than mucinous (52.8 percent) and adenocarcinoma (49.5 percent), and also had worse tumor grade (high grade: signet-ring cell, 73.5 percent; mucinous, 20.9 percent; adenocarcinoma, 17.5 percent).
  • Relative five-year survival was worse for signet-ring cell than mucinous or adenocarcinoma.
  • Although the incidence of colorectal adenocarcinoma is decreasing in the United States, mucinous and signet-ring cell subtypes are stable and increasing, respectively.
  • [MeSH-major] Adenocarcinoma, Mucinous / epidemiology. Carcinoma, Signet Ring Cell / epidemiology. Colonic Neoplasms / epidemiology. Rectal Neoplasms / epidemiology

  • Genetic Alliance. consumer health - Signet ring cell carcinoma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15868237.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


84. Yano H, Saito Y, Kirihara Y, Takashima J: Tumor invasion of lymph node capsules in patients with Dukes C colorectal adenocarcinoma. Dis Colon Rectum; 2006 Dec;49(12):1867-77
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor invasion of lymph node capsules in patients with Dukes C colorectal adenocarcinoma.
  • METHODS: We analyzed 480 positive lymph nodes from 155 consecutive patients with Stage III colorectal cancer to determine the frequency and significance of lymph node capsular invasion.
  • CONCLUSIONS: Lymph node capsular invasion, determined by routine hematoxylin-eosin staining, is a potent prognostic factor in Stage III colorectal cancer.
  • [MeSH-major] Adenocarcinoma / pathology. Colorectal Neoplasms / pathology. Lymph Nodes / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Dis Colon Rectum. 2007 Sep;50(9):1484; author reply 1484-5 [17661142.001]
  • (PMID = 17080279.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


85. Min BS, Kim NK, Ko YT, Baek SH, Lee KY, Sohn SK, Cho CH, Kang DR: Clinicopathological features of signet-ring cell carcinoma of the colon and rectum: a case-matched study. Hepatogastroenterology; 2009 Jul-Aug;56(93):984-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathological features of signet-ring cell carcinoma of the colon and rectum: a case-matched study.
  • BACKGROUND/AIMS: Primary colorectal signet-ring cell carcinoma (SRC) is a rare type of mucin-containing adenocarcinoma and little information exists about its clinicopathological features.
  • METHODS: The clinicopathological features of 27 patients with primary colorectal SRC were compared with non-signet-ring cell mucinous carcinoma (MC) and non-mucinous adenocarcinoma (NMC).
  • In stage II and III, SRC was found to be associated with a worse cancer-specific survival and a higher systemic recurrence rates than either NMC or MC.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Carcinoma, Signet Ring Cell / pathology. Colorectal Neoplasms / pathology

  • Genetic Alliance. consumer health - Signet ring cell carcinoma.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19760925.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  •  go-up   go-down


86. Sézeur A, Châtelet FP, Cywiner Ch, de Labriolle-Vaylet C, Chastang C, Billotey C, Malafosse M, Gallot D, Betton P, Montravers F, Carvajal-Gonzalez S, Askienazy S, Talbot JN, Rain JD, Milhaud G, Saumon G, Barbet J, Gruaz-Guyon A: Pathology underrates colon cancer extranodal and nodal metastases; ex vivo radioimmunodetection helps staging. Clin Cancer Res; 2007 Sep 15;13(18 Pt 2):5592s-5597s

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pathology underrates colon cancer extranodal and nodal metastases; ex vivo radioimmunodetection helps staging.
  • The benefit of adjuvant chemotherapy for patients upstaged with radioimmunodection should also be assessed because adjuvant chemotherapy improves the 5-year survival of stage III patients.
  • [MeSH-major] Adenocarcinoma / radionuclide imaging. Colonic Neoplasms / radionuclide imaging. Indium Radioisotopes. Radioimmunodetection

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17875794.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Bispecific; 0 / Carcinoembryonic Antigen; 0 / Haptens; 0 / Indium Radioisotopes; 0 / Oligopeptides
  •  go-up   go-down


87. Chang SC, Lin JK, Lin TC, Liang WY: Genetic alteration of p53, but not overexpression of intratumoral p53 protein, or serum p53 antibody is a prognostic factor in sporadic colorectal adenocarcinoma. Int J Oncol; 2005 Jan;26(1):65-75
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic alteration of p53, but not overexpression of intratumoral p53 protein, or serum p53 antibody is a prognostic factor in sporadic colorectal adenocarcinoma.
  • Of these, 20 were stage I (12%), 54 stage II (32.3%), 58 stage III (34.7%), and 35 stage IV (21%).
  • Genetic p53 alterations were associated with advanced tumor stage and tumor differentiation.
  • Of 132 potentially cured patients, 3-year disease-free survival (DFS) was affected by: advanced TNM stage (I, II, III: 90%, 84%, and 41%), genetic p53 alteration (89% vs. 43%), intratumoral p53 accumulation (71% vs. 56%), and preoperative CEA level >5 ng/ml (74% vs. 58%).
  • In multivariate analysis, genetic alteration of p53 was the most significant independent prognostic factor [hazard ratio (HR) = 6.09; 95% confidence interval (CI): 2.45-15.11], followed by advanced tumor stage (HR = 3.93; 95% CI: 2.14-7.23), and preoperative CEA >5 ng/ml (HR = 1.98; 95% CI: 1.12-3.17).
  • [MeSH-major] Adenocarcinoma / diagnosis. Biomarkers, Tumor / genetics. Colorectal Neoplasms / diagnosis. Tumor Suppressor Protein p53 / genetics

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15586226.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antibodies, Neoplasm; 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


88. Papagiorgis P, Oikonomakis I, Karapanagiotou I, Wexner SD, Nikiteas N: The impact of tumor location on the histopathologic expression of colorectal cancer. J BUON; 2006 Jul-Sep;11(3):317-21
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Cancer of the colon and rectum has been classically viewed as the same disease entity.
  • Since tumor pathology and staging is the major determinant of the disease outcome, comparison of these parameters between right and left colon cancer is reasonably expected to contribute to a better understanding of the nature of the adenocarcinoma of the colon.
  • Patients were divided into two groups according to the location of the tumor (right or left colon) and pathology between the two groups was compared.
  • Sixty individuals had right colon cancer, while 124 subjects had left colon lesions.
  • Dukes' A (stage I) colon cancer had statistically significant higher incidence in left colon lesions (p=0.0084).
  • Conversely, Dukes' C(stage III) tumors presented more often in the right colon (p=0.029).
  • Grade III lesions showed a clear superiority for the right colon (p=0.0014), while grade II lesions were more commonly found in the left colon (p=0.0201).
  • Grade III lesions were more common in the right colon (p=0.0200) when early colonic cancers (stage 0,I and II pooled together) were compared.
  • CONCLUSION: A shift in severity towards the right colon has been documented both in terms of stage and grade.
  • [MeSH-major] Adenocarcinoma / pathology. Colon / pathology. Colorectal Neoplasms / pathology

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17309156.001).
  • [ISSN] 1107-0625
  • [Journal-full-title] Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  • [ISO-abbreviation] J BUON
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


89. Niedzielska I, Niedzielski Z, Tkacz M, Orawczyk T, Ziaja K, Starzewski J, Mazurek U, Markowski J: Toll-like receptors and the tendency of normal mucous membrane to transform to polyp or colorectal cancer. J Physiol Pharmacol; 2009 May;60 Suppl 1:65-71
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Sixteen HG-U133A oligonucleotide microarrays were analysed including four of colonic polyps, four of adenocarcinoma with different degree of histological differentiation (2 poorly and 2 highly differentiated), and eight of macroscopically normal tissue.
  • An analysis of all per cent variability values with regard to malignancy stage increasing from polyp to stages I to III adenocarcinoma, and normal colon mucosa shows a statistically significant relationship for TLR2 (increasing) and TLR3 (decreasing).
  • In normal colon mucosa of polyposis patients the highest mRNA copy numbers were observed for TLR3, and the lowest for TLR7.
  • TLR3 may serve as a marker of colon tissue metaplasia and may indicate the tendency of normal tissue to form polyps transforming to colorectal cancer.
  • [MeSH-major] Adenocarcinoma / metabolism. Colonic Polyps / metabolism. Colorectal Neoplasms / metabolism. Mucous Membrane / metabolism. Toll-Like Receptors / biosynthesis
  • [MeSH-minor] Adult. Aged. Colon / metabolism. Colon / pathology. Female. Humans. Male. Middle Aged. Oligonucleotide Array Sequence Analysis. RNA, Messenger / biosynthesis

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19609015.001).
  • [ISSN] 1899-1505
  • [Journal-full-title] Journal of physiology and pharmacology : an official journal of the Polish Physiological Society
  • [ISO-abbreviation] J. Physiol. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / Toll-Like Receptors
  •  go-up   go-down


90. Silvéra L, Galula G, Tiret E, Louvet C, Leroux JL, Trutt B: Assessment of management practices for colonic cancer in the Paris metropolitan area in 2002. Gastroenterol Clin Biol; 2006 Jun-Jul;30(6-7):852-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To assess the management of patients aged 18 years or older with colonic adenocarcinoma (including the rectosigmoid junction), compared with French guidelines (ANAES and SOR).
  • METHODS: This retrospective study carried out in 2003 by the Ile-de-France regional union of health insurance funds from hospital discharge and operative and pathology reports of patients exempted from copayment between April 2001 and March 2002.
  • 37.7% of stage II patients had chemotherapy while 10.8% of stage III and 9.8% of stage IV patients did not.
  • CONCLUSION: Implementation of guidelines for the management of colon cancer can be improved, notably regarding pathologic analysis and indications of chemotherapy.
  • [MeSH-major] Adenocarcinoma / therapy. Colonic Neoplasms / therapy
  • [MeSH-minor] Adult. Age Factors. Aged. Aged, 80 and over. Colon / pathology. Data Collection. Data Interpretation, Statistical. Female. Guideline Adherence. Humans. Liver Neoplasms / secondary. Male. Middle Aged. Neoplasm Staging. Neoplasms, Multiple Primary / therapy. Paris. Practice Guidelines as Topic. Retrospective Studies. Surveys and Questionnaires

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16885869.001).
  • [ISSN] 0399-8320
  • [Journal-full-title] Gastroentérologie clinique et biologique
  • [ISO-abbreviation] Gastroenterol. Clin. Biol.
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] France
  •  go-up   go-down


91. Brozovich M, Read TE, Salgado J, Akbari RP, McCormick JT, Caushaj PF: Laparoscopic colectomy for apparently benign colorectal neoplasia: A word of caution. Surg Endosc; 2008 Feb;22(2):506-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • (1) a substantial fraction of patients undergoing laparoscopic colectomy for apparently benign colorectal neoplasia will have adenocarcinoma on final pathology; and (2) in our practice, we perform an adequate laparoscopic oncological resection for apparently benign polyps as evidenced by margin status and nodal retrieval.
  • Invasive adenocarcinoma was found on histological analysis of the colectomy specimen in 14 out of 63 cases (22%), standard error of the proportion 0.052.
  • Staging of the 14 cancers were I (n = 6, 43%), II (n = 3, 21%), III ( = 4, 29%), and IV (n = 1, 7%).
  • Neither dysplasia on endoscopic biopsy nor lesion diameter was predictive of adenocarcinoma.
  • Eight out of 23 (35%) patients with dysplasia on endoscopic biopsy had adenocarcinoma on final pathology versus 6/40 (15%) with no dysplasia (p = 0.114, Fisher's exact test).
  • CONCLUSION: A substantial fraction of endoscopically unresectable colorectal neoplasms with benign histology on initial biopsy will harbor invasive adenocarcinoma, some of advanced stage.
  • [MeSH-major] Adenocarcinoma / surgery. Colectomy / methods. Colonic Polyps / surgery. Colorectal Neoplasms / surgery. Laparoscopy

  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17704872.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


92. Fujita S, Yamamoto S, Akasu T, Moriya Y, Taniguchi H, Shimoda T: Quantification of CD10 mRNA in colorectal cancer and relationship between mRNA expression and liver metastasis. Anticancer Res; 2007 Sep-Oct;27(5A):3307-11
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • TIN was higher in colon, pN1/pN2, stage III and IV, and well- or moderately-differentiated adenocarcinoma than in rectum, pNO, stage I and II, and poorly-differentiated or mucinous adenocarcinoma, respectively.
  • Although CD10 mRNA was associated with invasion depth, lymph node status and TNM stage, it was not associated with prognosis.
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / immunology. Adenocarcinoma / pathology. Adenocarcinoma / secondary. Female. Humans. Male. Middle Aged. Neoplasm Staging. Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17970075.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / RNA, Messenger; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


93. Sugihara K, Kobayashi H, Kato T, Mori T, Mochizuki H, Kameoka S, Shirouzu K, Muto T: Indication and benefit of pelvic sidewall dissection for rectal cancer. Dis Colon Rectum; 2006 Nov;49(11):1663-72
Genetic Alliance. consumer health - Rectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Multivariate analysis disclosed a significantly increased incidence of positive lateral lymph nodes in female gender, lower rectal cancers, non-well-differentiated adenocarcinoma, tumor size of > or =4 cm and T3-T4.
  • The survival of patients with positive lateral lymph nodes was significantly worse than that of Stage III patients with negative lateral lymph nodes (45.8 vs. 71.2 percent, P<0.0001).
  • Multivariate analysis disclosed that lower rectal cancers, non-well-differentiated adenocarcinoma, T3-T4, perirectal lymph node metastasis, and positive lateral lymph nodes were significantly associated with an increased local recurrence.
  • [MeSH-major] Adenocarcinoma / surgery. Lymph Node Excision. Rectal Neoplasms / surgery. Rectum / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17041749.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


94. Nash GM, Gimbel M, Cohen AM, Zeng ZS, Ndubuisi MI, Nathanson DR, Ott J, Barany F, Paty PB: KRAS mutation and microsatellite instability: two genetic markers of early tumor development that influence the prognosis of colorectal cancer. Ann Surg Oncol; 2010 Feb;17(2):416-24
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PATIENTS AND METHODS: MSI and KRAS mutation status were assessed in 532 primary adenocarcinomas (stage I-IV) from patients treated by colon resection.
  • MSI was more common in early-stage disease (I, 15%; II, 21%; III, 10%; IV, 2%; P = 0.0001).
  • Prevalence of KRAS mutation did not vary with stage (I, 36%; II, 34%; III, 35%; IV, 40%; P = ns).
  • Using Cox regression analysis MSI, KRAS mutation, and stage were strong independent predictors of survival in the entire patient population.
  • A high-mortality group with MSS/KRAS-mutant tumors was identified within the stage I and II cohort.

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19813061.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P01 CA065930; United States / NCI NIH HHS / CA / 2 P01 CA65930-05A2
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Genetic Markers; 0 / KRAS protein, human; 0 / Proto-Oncogene Proteins; EC 3.6.5.2 / ras Proteins
  • [Other-IDs] NLM/ NIHMS674393; NLM/ PMC4380015
  •  go-up   go-down


95. Abe T, Hachiro Y, Kunimoto M: [Clinical usefulness of oral aprepitant for alleviation of delayed nausea and vomiting induced by mFOLFOX6--report of a case]. Gan To Kagaku Ryoho; 2010 Dec;37(13):2933-5
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 50-year-old-woman underwent high anterior resection for sigmoid colon adenocarcinoma.
  • Modified oxaliplatin/l / -LV/ 5-FU(mFOLFOX6)was started as adjuvant treatment due to final-stage III b.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antiemetics / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Morpholines / therapeutic use. Nausea / chemically induced. Nausea / drug therapy. Sigmoid Neoplasms / drug therapy. Vomiting / chemically induced. Vomiting / drug therapy

  • Genetic Alliance. consumer health - Nausea.
  • Genetic Alliance. consumer health - Vomiting.
  • MedlinePlus Health Information. consumer health - Nausea and Vomiting.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21160274.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antiemetics; 0 / Morpholines; 0 / Organoplatinum Compounds; 1NF15YR6UY / aprepitant; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; Folfox protocol
  •  go-up   go-down


96. Li SY, Liang ZJ, Yuan SJ, Yu B, Chen G, Zuo FY, Bai X, Chen G, Wei XJ, Xu YS, Cui W: [Clinical experience of 371 cases of sphincter-preservation with telescopic anastomosis after radical excision for low-middle rectal cancer]. Zhonghua Wei Chang Wai Ke Za Zhi; 2010 Apr;13(4):263-5
Genetic Alliance. consumer health - Rectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To evaluate the clinical efficacy, feasibility and safety of sphincter-preservation with telescopic anastomosis of colon and rectal mucosa in low-middle rectal cancer.
  • On histopathology, there were 361 adenocarcinomas, including 138 well-differentiated, 201 moderately differentiated, 11 poorly differentiated, 11 mucinous adenocarcinoma, and 10 adenomas with neoplastic changes.
  • According to the Duke's stage classification, 120 were TNM stage I, 222 stage II, 26 stage III, and 3 stage IV.
  • [MeSH-major] Adenocarcinoma / surgery. Anal Canal / surgery. Anastomosis, Surgical / methods. Rectal Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20422480.001).
  • [ISSN] 1671-0274
  • [Journal-full-title] Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  • [ISO-abbreviation] Zhonghua Wei Chang Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] China
  •  go-up   go-down


97. Nabeshima K, Machimura T, Wasada M, Takayasu H, Ogoshi K, Makuuchi H: A case of primary jejunal cancer diagnosed by preoperative small intestinal endoscopy. Tokai J Exp Clin Med; 2008 Apr;33(1):42-5
MedlinePlus Health Information. consumer health - Intestinal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Biopsy suggested a well-differentiated adenocarcinoma.
  • Under a diagnosis of primary jejunum cancer, Partial resection of the jejunum and partial resection of the transverse colon was performed.
  • Histopathologically, the tumor was well differentiated adenocarcinoma exposed serosal surface.
  • Postoperatively, the stage was evaluated as III (T3, N1, M0).
  • [MeSH-major] Adenocarcinoma / pathology. Endoscopy, Gastrointestinal. Intestine, Small / pathology. Jejunal Neoplasms / pathology. Preoperative Care

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21318964.001).
  • [ISSN] 2185-2243
  • [Journal-full-title] The Tokai journal of experimental and clinical medicine
  • [ISO-abbreviation] Tokai J. Exp. Clin. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


98. Chen CC, Yang SH, Lin JK, Lin TC, Chen WS, Jiang JK, Wang HS, Chang SC: Is it reasonable to add preoperative serum level of CEA and CA19-9 to staging for colorectal cancer? J Surg Res; 2005 Apr;124(2):169-74
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MATERIALS AND METHODS: The study population was patients (n = 574, 67.1 +/- 11.3 years old, 397 males) who received potentially curative resection of colorectal adenocarcinoma (stage I-III) between January 1994 and August 2002, including preoperative measurements of CEA and CA19-9.
  • However, the combined use of the two markers revealed a significant survival benefit (P = 0.035) of group 1 ("-" for both markers) over 4 ("+" for both) in stage II.
  • CONCLUSIONS: Patients with an elevated level of both CEA and CA19-9 in stage II of colorectal cancer have a significantly poorer prognosis than those with normal levels of these markers.
  • [MeSH-major] Adenocarcinoma / blood. Adenocarcinoma / pathology. CA-19-9 Antigen / blood. Carcinoembryonic Antigen / blood. Colorectal Neoplasms / blood. Colorectal Neoplasms / pathology

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15820244.001).
  • [ISSN] 0022-4804
  • [Journal-full-title] The Journal of surgical research
  • [ISO-abbreviation] J. Surg. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-19-9 Antigen; 0 / Carcinoembryonic Antigen
  •  go-up   go-down


99. Selvindos PB, Ho YH: Multimedia article. Laparoscopic ultralow anterior resection with colonic J-pouch-anal anastomosis. Dis Colon Rectum; 2008 Nov;51(11):1710-1

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patients with adenocarcinoma underwent preoperative endorectal ultrasound to individualize for neoadjuvant chemoradiotherapy, based on local extent and lymph nodes seen.
  • Ten patients (18 percent) had an American Society of Anesthesiologists' classification of III.
  • The indications were adenocarcinoma (n = 51), squamous-cell carcinoma of rectum (n = 1), dermoid tumor of mesorectum (n = 1), large villous adenoma (n = 1), and carcinoid with local lymph node metastases (n = 1).
  • The histologic grading or the adenocarcinoma patients were: Stage I, n = 14; Stage II, n = 23; Stage III, n = 11; Stage IV, n = 3.
  • Of those who underwent curative resection (Stages I-III), the distal resection margin was 2.9 +/- 0.7 cm (mean +/- standard error) and the radial resection margins were at least 2 mm in all patients.
  • At a median follow-up of 14 (2-33) months, none of the adenocarcinoma patients who had undergone curative resection had recurrences.
  • Four other patients had smaller pelvic collections that resolved with antibiotics; pelvic collections were associated with advanced stage of cancer (P = 0.047).
  • [MeSH-major] Adenocarcinoma / surgery. Anal Canal / surgery. Colonic Pouches. Laparoscopy / methods. Proctocolectomy, Restorative / methods. Rectal Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18679748.001).
  • [ISSN] 1530-0358
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Interactive Tutorial
  • [Publication-country] United States
  •  go-up   go-down


100. Sobczuk A, Smolarz B, Romanowicz-Makowska H, Pertyński T: MMAC/PTEN gene expression in endometrial cancer: RT-PCR studies. Pol J Pathol; 2006;57(3):137-40
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Mutations in the MMAC/PTEN (phosphatase and tensin homologue deleted on chromosome 10) gene are documented in cancers of the breast, prostate, ovary, colon, melanoma, glioblastoma, lymphoma and endometrium.
  • In the present work MMAC/PTEN gene expression in women with endometrial adenocarcinoma (n=70) in RNA samples obtained from cancer tissue were investigated.
  • The expression of MMAC/PTEN gene in endometrial adenocarcinoma cases was significantly reduced compared to the expression in the normal samples (P < 0.05).
  • Furthermore the significant difference (P < 0.05) was observed between the expression of MMAC/PTEN in stage III versus lower stages of endometrial cancer.
  • [MeSH-major] Adenocarcinoma / genetics. Biomarkers, Tumor / genetics. Endometrial Neoplasms / genetics. Gene Expression. PTEN Phosphohydrolase / genetics

  • Genetic Alliance. consumer health - Endometrial cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17219740.001).
  • [ISSN] 1233-9687
  • [Journal-full-title] Polish journal of pathology : official journal of the Polish Society of Pathologists
  • [ISO-abbreviation] Pol J Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Messenger; EC 3.1.3.48 / PTEN protein, human; EC 3.1.3.67 / PTEN Phosphohydrolase
  •  go-up   go-down






Advertisement